FR09C0065I2 - Derives de quinazoline - Google Patents

Derives de quinazoline

Info

Publication number: FR09C0065I2
Authority: FR; France
Prior art keywords: quinazoline derivatives; quinazoline; derivatives
Prior art date: 1995-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR09C0065C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AstraZeneca AB

Original Assignee

AstraZeneca AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-27

Filing date

2009-12-15

Publication date

2014-03-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10773597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0065(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-15 Application filed by AstraZeneca AB filed Critical AstraZeneca AB

2010-01-22 Publication of FR09C0065I1 publication Critical patent/FR09C0065I1/fr

2014-03-28 Application granted granted Critical

2014-03-28 Publication of FR09C0065I2 publication Critical patent/FR09C0065I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

FR09C0065C 1995-04-27 2009-12-15 Derives de quinazoline Active FR09C0065I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9508538.7A GB9508538D0 (en)	1995-04-27	1995-04-27	Quinazoline derivatives
PCT/GB1996/000961 WO1996033980A1 (en)	1995-04-27	1996-04-23	Quinazoline derivatives

Publications (2)

Publication Number	Publication Date
FR09C0065I1 FR09C0065I1 (es)	2010-01-22
FR09C0065I2 true FR09C0065I2 (fr)	2014-03-28

Family

ID=10773597

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR09C0065C Active FR09C0065I2 (fr)	1995-04-27	2009-12-15	Derives de quinazoline

Country Status (38)

Country	Link
US (1)	US5770599A (es)
EP (1)	EP0823900B1 (es)
JP (1)	JP3040486B2 (es)
KR (1)	KR100296656B1 (es)
CN (1)	CN1100046C (es)
AR (1)	AR003944A1 (es)
AT (1)	ATE198329T1 (es)
AU (1)	AU699163B2 (es)
BG (1)	BG62730B1 (es)
BR (1)	BRPI9608082B8 (es)
CA (1)	CA2215732C (es)
CZ (1)	CZ288489B6 (es)
DE (2)	DE122009000076I1 (es)
DK (1)	DK0823900T3 (es)
EE (1)	EE03482B1 (es)
EG (1)	EG24134A (es)
ES (1)	ES2153098T3 (es)
FR (1)	FR09C0065I2 (es)
GB (1)	GB9508538D0 (es)
GR (1)	GR3035211T3 (es)
HR (1)	HRP960204B1 (es)
HU (1)	HU223313B1 (es)
IL (1)	IL118045A (es)
LU (1)	LU91631I2 (es)
MY (1)	MY114425A (es)
NL (1)	NL300429I1 (es)
NO (2)	NO309472B1 (es)
NZ (1)	NZ305444A (es)
PL (1)	PL189182B1 (es)
PT (1)	PT823900E (es)
RO (1)	RO117849B1 (es)
RU (1)	RU2153495C2 (es)
SI (1)	SI0823900T1 (es)
SK (1)	SK282236B6 (es)
TW (1)	TW436486B (es)
UA (1)	UA52602C2 (es)
WO (1)	WO1996033980A1 (es)
ZA (1)	ZA963358B (es)

Families Citing this family (747)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6811779B2 (en)	1994-02-10	2004-11-02	Imclone Systems Incorporated	Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
TW321649B (es) *	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
WO1996033977A1 (en) *	1995-04-27	1996-10-31	Zeneca Limited	Quinazoline derivatives
GB9508537D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508535D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
GB9508565D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
US7060808B1 (en) *	1995-06-07	2006-06-13	Imclone Systems Incorporated	Humanized anti-EGF receptor monoclonal antibody
GB9624482D0 (en) *	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
BR9707495A (pt)	1996-02-13	1999-07-27	Zeneca Ltd	Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
GB9603097D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
AU719327B2 (en)	1996-03-05	2000-05-04	Astrazeneca Ab	4-anilinoquinazoline derivatives
NZ332119A (en)	1996-04-12	2001-08-31	Warner Lambert Co	Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
GB9607729D0 (en) *	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
NZ502646A (en) *	1997-08-15	2002-04-26	Cephalon Inc	A synergistic combination of tyrosine kinase inhibitors and chemical castration agents
ES2289791T3 (es)	1997-08-22	2008-02-01	Astrazeneca Ab	Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
US20030224001A1 (en) *	1998-03-19	2003-12-04	Goldstein Neil I.	Antibody and antibody fragments for inhibiting the growth of tumors
US6864227B1 (en)	1998-04-13	2005-03-08	California Institute Of Technology	Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) *	1998-04-13	2005-05-03	California Institute Of Technology	Artery- and vein-specific proteins and uses therefor
ZA200007412B (en) *	1998-05-15	2002-03-12	Imclone Systems Inc	Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US7354894B2 (en) *	1998-08-18	2008-04-08	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
EE200100097A (et)	1998-08-18	2002-06-17	The Regents Of The University Of California	Hingamisteede lima tootmise tõkestamine EGF-R antagonistide manustamise teel
MXPA01001893A (es)	1998-08-21	2002-04-24	Parker Hughes Inst	Derivados de quinazolina.
EP1950201A1 (en)	1998-09-29	2008-07-30	Wyeth Holdings Corporation	Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US6297258B1 (en)	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
US6288082B1 (en)	1998-09-29	2001-09-11	American Cyanamid Company	Substituted 3-cyanoquinolines
DK1135153T3 (da) *	1998-11-20	2005-08-15	Genentech Inc	Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
ID29800A (id)	1999-02-27	2001-10-11	Boehringer Ingelheim Pharma	Turunan-turunan 4-amino-kinazolin dan kinolin yang mempunyai efek inhibitor pada transduksi signal yang dimediasi oleh tirosin kinase
DE19911509A1 (de) *	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU782994C (en) *	1999-05-14	2006-08-24	Imclone Llc	Treatment of refractory human tumors with epidermal growth factor receptor antagonists
MXPA01012899A (es)	1999-06-21	2002-07-30	Boehringer Ingelheim Pharma	Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
US6432979B1 (en)	1999-08-12	2002-08-13	American Cyanamid Company	Method of treating or inhibiting colonic polyps and colorectal cancer
GB9925958D0 (en) *	1999-11-02	1999-12-29	Bundred Nigel J	Therapeutic use
PL203782B1 (pl)	1999-11-05	2009-11-30	Astrazeneca Ab	Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
US20020002169A1 (en)	1999-12-08	2002-01-03	Griffin John H.	Protein kinase inhibitors
GB0002952D0 (en) *	2000-02-09	2000-03-29	Pharma Mar Sa	Process for producing kahalalide F compounds
GB0007371D0 (en)	2000-03-28	2000-05-17	Astrazeneca Uk Ltd	Chemical compounds
GB0008368D0 (en) *	2000-04-06	2000-05-24	Astrazeneca Ab	Combination product
CA2403365A1 (en)	2000-04-07	2001-10-18	Astrazeneca Ab	Quinazoline compounds
EP1170011A1 (en) *	2000-07-06	2002-01-09	Boehringer Ingelheim International GmbH	Novel use of inhibitors of the epidermal growth factor receptor
JP2004527456A (ja) *	2000-08-09	2004-09-09	イムクローンシステムズインコーポレイティド	Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
US6656946B2 (en)	2000-08-26	2003-12-02	Boehringer Ingelheim Pharma Kg	Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042059A1 (de) *	2000-08-26	2002-03-07	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6617329B2 (en)	2000-08-26	2003-09-09	Boehringer Ingelheim Pharma Kg	Aminoquinazolines and their use as medicaments
US6403580B1 (en)	2000-08-26	2002-06-11	Boehringer Ingelheim Pharma Kg	Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10042058A1 (de) *	2000-08-26	2002-03-07	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6740651B2 (en)	2000-08-26	2004-05-25	Boehringer Ingelheim Pharma Kg	Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
WO2002030926A1 (en) *	2000-10-13	2002-04-18	Astrazeneca Ab	Quinazoline derivatives
EP1415987B1 (en)	2000-10-20	2007-02-28	Eisai R&D Management Co., Ltd.	Nitrogenous aromatic ring compounds as anti cancer agents
DE10206505A1 (de) *	2002-02-16	2003-08-28	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern
US7776315B2 (en)	2000-10-31	2010-08-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE60144284D1 (de) *	2000-11-01	2011-05-05	Millennium Pharm Inc	Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
EP1363627A2 (en)	2001-02-19	2003-11-26	Novartis AG	Treatment of solid tumours with rapamycin derivatives
US20080008704A1 (en) *	2001-03-16	2008-01-10	Mark Rubin	Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20040167134A1 (en)	2001-05-16	2004-08-26	Christian Bruns	Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
AU2002350105A1 (en)	2001-06-21	2003-01-08	Ariad Pharmaceuticals, Inc.	Novel quinazolines and uses thereof
MXPA04006260A (es) *	2001-12-24	2005-03-31	Astrazeneca Ab	Derivados de quinazolina sustituidos como inhibidores de cinasas aurora.
DE10204462A1 (de) *	2002-02-05	2003-08-07	Boehringer Ingelheim Pharma	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US20050130995A1 (en)	2002-02-06	2005-06-16	Ube Industries, Ltd.	Process for producing 4-aminoquinazoline compound
GB0204392D0 (en) *	2002-02-26	2002-04-10	Astrazeneca Ab	Pharmaceutical compound
PL208114B1 (pl)	2002-02-26	2011-03-31	Astrazeneca Ab	Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie
ES2342660T3 (es) *	2002-02-26	2010-07-12	Astrazeneca Ab	Nuevas formas cristalinas del compuesto anticancerigeno zd1839.
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
GB0206215D0 (en) *	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
RU2345989C2 (ru) *	2002-03-28	2009-02-10	Астразенека Аб	Производные 4-анилино-хиназолина, способ их получения (варианты), фармацевтическая композиция, способ ингибирования пролиферативного действия и способ лечения рака у теплокровного животного
TW200813014A (en) *	2002-03-28	2008-03-16	Astrazeneca Ab	Quinazoline derivatives
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20050215530A1 (en) *	2002-04-16	2005-09-29	Ryan Anderson J	Combination therapy for the treatment of cancer
DE10221018A1 (de) *	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
AU2003240655B2 (en)	2002-05-16	2007-09-06	Novartis Ag	Use of EDG receptor binding agents in cancer
US20040048887A1 (en) *	2002-07-09	2004-03-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
ES2376165T3 (es)	2002-07-15	2012-03-09	F. Hoffmann-La Roche Ag	Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
US7576074B2 (en) *	2002-07-15	2009-08-18	Rice Kenneth D	Receptor-type kinase modulators and methods of use
GB0221245D0 (en) *	2002-09-13	2002-10-23	Astrazeneca Ab	Chemical process
EP3321282A1 (en)	2002-09-27	2018-05-16	Xencor, Inc.	Optimized fc variants and methods for their generation
GB0223854D0 (en) *	2002-10-12	2002-11-20	Astrazeneca Ab	Therapeutic treatment
GB0304367D0 (en) *	2003-02-26	2003-04-02	Pharma Mar Sau	Methods for treating psoriasis
AU2003278383B2 (en) *	2002-11-04	2007-06-14	Astrazeneca Ab	Quinazoline derivatives as Src tyrosine kinase inhibitors
WO2004046101A2 (en)	2002-11-20	2004-06-03	Array Biopharma, Inc.	Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
US20060167026A1 (en) *	2003-01-06	2006-07-27	Hiroyuki Nawa	Antipsychotic molecular-targeting epithelial growth factor receptor
CN102558155A (zh)	2003-01-14	2012-07-11	阿伦纳药品公司	作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
GB0302882D0 (en) *	2003-02-07	2003-03-12	Univ Cardiff	Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
US7223749B2 (en)	2003-02-20	2007-05-29	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
ATE508747T1 (de)	2003-03-10	2011-05-15	Eisai R&D Man Co Ltd	C-kit kinase-hemmer
JP2006521111A (ja) *	2003-03-12	2006-09-21	バスジーンセラピューティクス，インコーポレイテッド	血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
US7381410B2 (en) *	2003-03-12	2008-06-03	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1622941A2 (en) *	2003-03-20	2006-02-08	ImClone Systems Incorporated	Method of producing an antibody to epidermal growth factor receptor
GB0309850D0 (en)	2003-04-30	2003-06-04	Astrazeneca Ab	Quinazoline derivatives
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent
EP2644195A1 (en)	2003-05-19	2013-10-02	Irm Llc	Immunosuppressant Compounds and Compositions
MY150088A (en)	2003-05-19	2013-11-29	Irm Llc	Immunosuppressant compounds and compositions
JO2785B1 (en)	2003-05-27	2014-03-15	شركة جانسين فارماسوتيكا ان. في	Quinazoline derivatives
JP4724657B2 (ja)	2003-05-30	2011-07-13	アストラゼネカユーケーリミテッド	プロセス
DE10326186A1 (de)	2003-06-06	2004-12-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2005001053A2 (en)	2003-06-09	2005-01-06	Samuel Waksal	Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN103755807A (zh)	2003-07-18	2014-04-30	安姆根有限公司	肝细胞生长因子的特异性结合物
GB0317665D0 (en)	2003-07-29	2003-09-03	Astrazeneca Ab	Qinazoline derivatives
GB0317663D0 (en) *	2003-07-29	2003-09-03	Astrazeneca Ab	Pharmaceutical composition
WO2005012290A1 (en) *	2003-07-29	2005-02-10	Astrazeneca Ab	Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
WO2005016346A1 (en) *	2003-08-14	2005-02-24	Array Biopharma Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
GB0320793D0 (en) *	2003-09-05	2003-10-08	Astrazeneca Ab	Chemical process
GB0321066D0 (en) *	2003-09-09	2003-10-08	Pharma Mar Sau	New antitumoral compounds
EP1664030A1 (en) *	2003-09-16	2006-06-07	AstraZeneca AB	Quinazoline derivatives
ES2305844T3 (es) *	2003-09-16	2008-11-01	Astrazeneca Ab	Derivados de quinazolina como inhibidores de tirosina cinasa.
DE602004004553T2 (de) *	2003-09-19	2007-10-25	Astrazeneca Ab	Chinazolinderivate
US20070037837A1 (en) *	2003-09-19	2007-02-15	Hennequin Laurent Francois A	Quinazoline derivatives
GB0322409D0 (en)	2003-09-25	2003-10-29	Astrazeneca Ab	Quinazoline derivatives
BRPI0414735A (pt) *	2003-09-25	2006-11-21	Astrazeneca Ab	derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina
PL2392565T3 (pl) *	2003-09-26	2014-08-29	Exelixis Inc	Modulatory c-Met i sposoby stosowania
US7456189B2 (en)	2003-09-30	2008-11-25	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (de)	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
NZ547633A (en)	2003-11-06	2010-08-27	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
WO2005044788A1 (ja)	2003-11-11	2005-05-19	Eisai Co., Ltd.	ウレア誘導体およびその製造方法
GB0326459D0 (en)	2003-11-13	2003-12-17	Astrazeneca Ab	Quinazoline derivatives
WO2005058913A1 (en)	2003-12-18	2005-06-30	Janssen Pharmaceutica N.V.	Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
US20050221501A1 (en) *	2003-12-24	2005-10-06	Arnot Kate I	Dissolution method
WO2005070909A1 (en) *	2004-01-22	2005-08-04	Natco Pharma Limited	An improved process for the preparation of gefitinib
ES2315834T3 (es)	2004-02-03	2009-04-01	Astrazeneca Ab	Derivados de quinazolina.
CA2559554A1 (en) *	2004-03-12	2005-09-29	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
KR20120123619A (ko)	2004-03-12	2012-11-08	바스진 테라퓨틱스, 인크.	혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
JP4734319B2 (ja)	2004-03-19	2011-07-27	イムクローン・リミテッド・ライアビリティ・カンパニー	ヒト抗上皮成長因子受容体抗体
WO2005097137A2 (en) *	2004-03-31	2005-10-20	The Scripps Research Institute	Advanced quinazoline based protein kinase inhibitors
ES2741546T3 (es)	2004-03-31	2020-02-11	Massachusetts Gen Hospital	Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
BRPI0509721A (pt)	2004-04-07	2007-09-25	Novartis Ag	inibidores de iap
SI1746999T1 (sl)	2004-05-06	2012-01-31	Warner Lambert Co	4-fenilamino-kinazolin-6-il-amidi
BRPI0510717B8 (pt)	2004-05-06	2021-05-25	Bioresponse Llc	uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr)
AU2005249490B2 (en)	2004-06-01	2010-07-29	Genentech, Inc.	Antibody drug conjugates and methods
GB0512324D0 (en)	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
EP1765313A2 (en)	2004-06-24	2007-03-28	Novartis Vaccines and Diagnostics, Inc.	Compounds for immunopotentiation
SI2471813T1 (sl)	2004-07-15	2015-03-31	Xencor, Inc.	Optimirane Fc variante
AU2005283422C1 (en)	2004-09-17	2017-02-02	Eisai R & D Management Co., Ltd.	Medicinal composition
KR101270829B1 (ko)	2004-09-23	2013-06-07	제넨테크, 인크.	시스테인 유전자조작 항체 및 접합체
ES2529451T3 (es) *	2004-09-23	2015-02-20	Vasgene Therapeutics, Inc.	Compuestos polipeptídicos para inhibir la angiogénesis y el crecimiento tumoral
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
CA2587642C (en)	2004-11-30	2013-04-09	Amgen Inc.	Substituted heterocycles and methods of use
JO3088B1 (ar) *	2004-12-08	2017-03-15	Janssen Pharmaceutica Nv	مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es)	2004-12-08	2019-05-10	Janssen Pharmaceutica Nv	Derivados de quinazolina inhibidores de cinasas dirigidos a multip
DE602005026865D1 (de)	2004-12-14	2011-04-21	Astrazeneca Ab	Pyrazolopyrimidinverbindungen als antitumormittel
ATE497762T1 (de)	2004-12-30	2011-02-15	Bioresponse Llc	Verwendung von diindolylmethan-verwandten indolen zur behandlung und prävention von erkrankungen im zusammenhang mit dem respiratory syncytial virus
DOP2006000010A (es)	2005-01-10	2006-07-31	Arena Pharm Inc	Procedimiento para preparar eteres aromáticos
CN101146532B (zh)	2005-01-21	2012-05-09	阿斯泰克斯治疗有限公司	药物化合物
BRPI0518104B8 (pt)	2005-01-21	2021-05-25	Genentech Inc	artigo industrializado e uso de anticorpo her2
GB0501999D0 (en) *	2005-02-01	2005-03-09	Sentinel Oncology Ltd	Pharmaceutical compounds
BRPI0606839B8 (pt)	2005-02-03	2021-12-14	Massachusetts Gen Hospital	Uso de uma composição farmacêutica compreendendo um inibidor irreversível de receptor de fator de crescimento epidérmico (egfr)
US20060188498A1 (en) *	2005-02-18	2006-08-24	Genentech, Inc.	Methods of using death receptor agonists and EGFR inhibitors
US20090155247A1 (en) *	2005-02-18	2009-06-18	Ashkenazi Avi J	Methods of Using Death Receptor Agonists and EGFR Inhibitors
WO2006090413A1 (en) *	2005-02-23	2006-08-31	Natco Pharma Limited	Novel crystalline form of gefitinib and a process for its preparation
RU2404806C2 (ru)	2005-02-23	2010-11-27	Дженентек, Инк.	Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
JP5054544B2 (ja)	2005-02-26	2012-10-24	アストラゼネカアクチボラグ	チロシンキナーゼ阻害剤としてのキナゾリン誘導体
CN101163468A (zh)	2005-02-28	2008-04-16	卫材R&D管理有限公司	磺酰胺化合物的新联合用途
US20060216288A1 (en) *	2005-03-22	2006-09-28	Amgen Inc	Combinations for the treatment of cancer
AU2006235487B2 (en) *	2005-04-12	2011-12-22	Elan Pharma International Limited	Nanoparticulate quinazoline derivative formulations
LT1871347T (lt)	2005-04-19	2016-11-10	Novartis Ag	Farmacinė kompozicija
WO2006119674A1 (en) *	2005-05-12	2006-11-16	Wenlin Huang	The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
WO2006119676A1 (en) *	2005-05-12	2006-11-16	Wenlin Huang	The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
CN101175732B (zh) *	2005-05-12	2010-06-16	黄文林	一种喹唑啉衍生物的制备方法及用作制备治疗肿瘤疾病药物的应用
DK1885187T3 (da)	2005-05-13	2013-12-09	Novartis Ag	Fremgangsmåde til behandling af lægemiddelresistent cancer
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
CA2680945C (en)	2005-06-17	2014-03-18	Imclone Systems Incorporated	Anti-pdgfralpha antibodies
EP2004695A2 (en)	2005-07-08	2008-12-24	Xencor, Inc.	Optimized anti-ep-cam antibodies
BRPI0613783A2 (pt) *	2005-07-18	2011-02-01	Bipar Sciences Inc	tratamento de cáncer
EP1925941B1 (en) *	2005-08-01	2012-11-28	Eisai R&D Management Co., Ltd.	Method for prediction of the efficacy of vascularization inhibitor
EP2281901B1 (en)	2005-08-02	2013-11-27	Eisai R&D Management Co., Ltd.	Anti-tumour pharmaceutical composition with angiogenesis inhibitors
US8129114B2 (en)	2005-08-24	2012-03-06	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
CN1300118C (zh) *	2005-08-25	2007-02-14	江苏吴中苏药医药开发有限责任公司	4－(3－氯－4－氟苯基胺基)－7－甲氧基－6－(3－吗啉丙氧基)喹唑啉的制备方法
CN101277720A (zh) *	2005-09-01	2008-10-01	卫材R&D管理有限公司	崩解性被改善的药物组合物的制备方法
DE602006018331D1 (de)	2005-09-20	2010-12-30	Astrazeneca Ab	4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
US20070218061A1 (en) *	2005-09-23	2007-09-20	Vasgene Therapeutics, Inc.	Use of ephrinb2 directed agents for the treatment or prevention of viral infections
RU2451524C2 (ru)	2005-11-04	2012-05-27	Вайет	Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
CA2627598C (en)	2005-11-07	2013-06-25	Eisai R & D Management Co., Ltd.	Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
CA2833706C (en)	2005-11-11	2014-10-21	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
ES2481671T3 (es)	2005-11-21	2014-07-31	Novartis Ag	Inhibidores de mTOR en el tratamiento de tumores endocrinos
WO2007061127A1 (ja) *	2005-11-22	2007-05-31	Eisai R & D Management Co., Ltd.	多発性骨髄腫に対する抗腫瘍剤
US7977346B2 (en) *	2006-01-17	2011-07-12	Guoqing Paul Chen	Spiro compounds and methods of use
CN101003514A (zh)	2006-01-20	2007-07-25	上海艾力斯医药科技有限公司	喹唑啉衍生物、其制备方法及用途
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
AR059066A1 (es)	2006-01-27	2008-03-12	Amgen Inc	Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
PE20070978A1 (es) *	2006-02-14	2007-11-15	Novartis Ag	COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
GB0605120D0 (en)	2006-03-14	2006-04-26	Novartis Ag	Organic Compounds
US20070231298A1 (en) *	2006-03-31	2007-10-04	Cell Genesys, Inc.	Cytokine-expressing cancer immunotherapy combinations
MX2008012715A (es)	2006-04-05	2008-10-14	Novartis Ag	Combinaciones de agentes terapeuticos para el tratamiento de cancer.
AU2007234382B2 (en)	2006-04-05	2011-06-09	Novartis Ag	Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
AR060358A1 (es) *	2006-04-06	2008-06-11	Novartis Vaccines & Diagnostic	Quinazolinas para la inhibicion de pdk 1
KR20080110912A (ko)	2006-04-19	2008-12-19	노파르티스 아게	인다졸 화합물 및 ｃｄｃ７의 억제 방법
AR060635A1 (es)	2006-04-27	2008-07-02	Banyu Pharma Co Ltd	Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
MX2008014292A (es)	2006-05-09	2008-11-18	Novartis Ag	Combinacion que comprende un quelante de hierro y un agente anti-neoplastico, y uso de la misma.
WO2007136103A1 (ja) *	2006-05-18	2007-11-29	Eisai R & D Management Co., Ltd.	甲状腺癌に対する抗腫瘍剤
US20100279327A1 (en) *	2006-06-12	2010-11-04	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
US20070292883A1 (en) *	2006-06-12	2007-12-20	Ossovskaya Valeria S	Method of treating diseases with PARP inhibitors
EP2044939A1 (en) *	2006-06-29	2009-04-08	Eisai R&D Management Co., Ltd.	Therapeutic agent for liver fibrosis
ES2569428T3 (es)	2006-07-13	2016-05-10	Janssen Pharmaceutica Nv	Derivados de quinazolina como MTKI
PE20080403A1 (es)	2006-07-14	2008-04-25	Amgen Inc	Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en)	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
US8524867B2 (en)	2006-08-14	2013-09-03	Xencor, Inc.	Optimized antibodies that target CD19
WO2008026748A1 (en)	2006-08-28	2008-03-06	Eisai R & D Management Co., Ltd.	Antitumor agent for undifferentiated gastric cancer
JP2008081492A (ja)	2006-08-31	2008-04-10	Banyu Pharmaceut Co Ltd	オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
CN101534836B (zh) *	2006-09-05	2011-09-28	彼帕科学公司	Parp抑制剂在制备治疗肥胖症的药物中的用途
EP2059498A4 (en) *	2006-09-05	2011-01-12	Bipar Sciences Inc	TREATMENT OF CANCER
EP2061469B8 (en) *	2006-09-11	2014-02-26	Curis, Inc.	Quinazoline based egfr inhibitors
ATE522625T1 (de)	2006-09-12	2011-09-15	Genentech Inc	Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
RU2492864C2 (ru)	2006-09-18	2013-09-20	Бёрингер Ингельхайм Интернациональ Гмбх	Способ лечения рака, несущего мутации egfr
EP2081933B1 (en)	2006-09-29	2011-03-23	Novartis AG	Pyrazolopyrimidines as pi3k lipid kinase inhibitors
US8916552B2 (en)	2006-10-12	2014-12-23	Astex Therapeutics Limited	Pharmaceutical combinations
US8883790B2 (en)	2006-10-12	2014-11-11	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008046242A1 (fr) *	2006-10-16	2008-04-24	Institute Of Mataria Medica, Chinese Academy Of Medical Sciences	Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations
BRPI0717753B1 (pt)	2006-10-27	2022-04-12	Bioresponse, Llc	Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição
KR20090091119A (ko) *	2006-10-27	2009-08-26	얀센 파마슈티카 엔.브이.	뇌암을 치료하거나 예방하기 위한 ｍｔ 키나아제 저해제의 용도
US7851623B2 (en)	2006-11-02	2010-12-14	Astrazeneca Ab	Chemical process
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
US20100098641A1 (en) *	2006-12-13	2010-04-22	William Baker	Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction
CA2672438A1 (en)	2006-12-20	2008-07-03	Amgen Inc.	Substituted heterocycles and methods of use
US7977336B2 (en)	2006-12-28	2011-07-12	Banyu Pharmaceutical Co. Ltd	Aminopyrimidine derivatives as PLK1 inhibitors
EP2118069B1 (en)	2007-01-09	2014-01-01	Amgen Inc.	Bis-aryl amide derivatives useful for the treatment of cancer
EP2119707B1 (en)	2007-01-29	2015-01-14	Eisai R&D Management Co., Ltd.	Composition for treatment of undifferentiated-type of gastric cancer
US7998949B2 (en)	2007-02-06	2011-08-16	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
CA2677651A1 (en)	2007-02-15	2008-08-21	Novartis Ag	Combinations of therapeutic agents for treating cancer
MX2009008531A (es)	2007-02-16	2009-08-26	Amgen Inc	Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
CA2677108A1 (en)	2007-03-02	2008-09-12	Genentech, Inc.	Predicting response to a her inhibitor
WO2008121346A1 (en) *	2007-03-30	2008-10-09	Massachusetts Institute Of Technology	Methods for identifying compounds that modulate neurotrophic factor signaling
EP2155656A2 (en)	2007-04-16	2010-02-24	Cipla Limited	Process for the preparation of gefitinib
DK2176298T3 (en)	2007-05-30	2018-02-12	Xencor Inc	Methods and compositions for inhibiting CD32B-expressing cells
WO2008154249A2 (en)	2007-06-08	2008-12-18	Genentech, Inc.	Gene expression markers of tumor resistance to her2 inhibitor treatment
ES2435454T3 (es) *	2007-06-21	2013-12-19	Janssen Pharmaceutica, N.V.	Indolin-2-onas y aza-indolin-2-onas
EP2185562B1 (en)	2007-07-27	2015-12-02	Janssen Pharmaceutica, N.V.	Pyrrolopyrimidines useful for the treatment of proliferative diseases
BRPI0815399A2 (pt) *	2007-08-13	2019-09-24	Vasgene Therapeutics Inc	tratamento de câncer usando anticorpos humanizados que se ligam ephb4
SI2188313T1 (en)	2007-08-21	2018-04-30	Amgen, Inc.	HUMAN C-FMS ANTIGEN TRANSFER PROTEIN
JP5474792B2 (ja) *	2007-09-10	2014-04-16	キュリス，インコーポレイテッド	亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101903025A (zh) *	2007-10-19	2010-12-01	彼帕科学公司	利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
CN101861159A (zh) *	2007-10-19	2010-10-13	马尔药品公司	改进的抗肿瘤治疗
EP2213673B1 (en)	2007-10-23	2013-06-05	Msd K.K.	Pyridone-substituted-dihydropyrazolopyrimidinone derivative
CA2703767A1 (en) *	2007-10-29	2009-05-07	Natco Pharma Limited	Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
CA2704000C (en)	2007-11-09	2016-12-13	Eisai R&D Management Co., Ltd.	Combination of anti-angiogenic substance and anti-tumor platinum complex
JP2011503071A (ja) *	2007-11-12	2011-01-27	バイパーサイエンシズ，インコーポレイティド	Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる子宮がん及び卵巣がんの治療
NZ586125A (en) *	2007-11-12	2012-12-21	Bipar Sciences Inc	Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2009067543A2 (en) *	2007-11-19	2009-05-28	The Regents Of The University Of Colorado	Treatment of histone deacetylase mediated disorders
CL2008003449A1 (es)	2007-11-21	2010-02-19	Imclone Llc	Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
MX2010006154A (es) *	2007-12-07	2010-09-24	Bipar Sciences Inc	Tratamiento del cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de la poli-adp-ribosa-polimerasa.
UY31545A1 (es)	2007-12-20	2009-08-03		Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
AU2008347940A1 (en)	2008-01-18	2009-07-23	Natco Pharma Limited	6,7-dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
EP2242493B1 (en) *	2008-01-22	2013-06-05	Concert Pharmaceuticals Inc.	Derivatives of gefitinib
KR101506062B1 (ko) *	2008-01-29	2015-03-25	에자이 알앤드디 매니지먼트 가부시키가이샤	혈관 저해 물질과 탁산의 병용
AU2009209541A1 (en) *	2008-01-30	2009-08-06	Pharma Mar, S.A.	Improved antitumoral treatments
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0907916A2 (pt)	2008-02-07	2015-07-28	Boehringer Ingelheim Int	Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
CN105343102A (zh) *	2008-03-05	2016-02-24	诺华股份有限公司	嘧啶衍生物在治疗egfr依赖性疾病或对靶向egfr家族成员的物质具有获得性耐药性的疾病中的用途
RU2010140890A (ru) *	2008-03-07	2012-04-20	Фарма Мар, С.А. (Es)	Улучшенные способы противоопухолевого лечения
KR101673621B1 (ko)	2008-03-24	2016-11-07	노파르티스 아게	아릴술폰아미드-계 매트릭스 메탈로프로테아제 억제제
CN101544609A (zh)	2008-03-25	2009-09-30	上海艾力斯医药科技有限公司	4-苯胺喹唑啉衍生物的结晶形式
ES2519474T3 (es)	2008-03-26	2014-11-07	Novartis Ag	Inhibidores de las desacetilasas B basados en hidroxamato
WO2009138781A1 (en)	2008-05-13	2009-11-19	Astrazeneca Ab	Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
ES2430590T3 (es)	2008-05-14	2013-11-21	Genomic Health, Inc.	Predictores de la respuesta de pacientes al tratamiento con inhibidores del receptor del EGF
CN101584696A (zh) *	2008-05-21	2009-11-25	上海艾力斯医药科技有限公司	包含喹唑啉衍生物的组合物及制备方法、用途
SG191676A1 (en)	2008-06-17	2013-07-31	Wyeth Llc	Antineoplastic combinations containing hki-272 and vinorelbine
DE102008031040A1 (de)	2008-06-30	2009-12-31	Alexander Priv.-Doz. Dr. Dömling	Iressa zur Anwendung in der Organtransplantation
CN109464445A (zh)	2008-08-04	2019-03-15	惠氏有限责任公司	4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
US8648191B2 (en)	2008-08-08	2014-02-11	Boehringer Ingelheim International Gmbh	Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
CN101367793B (zh) *	2008-09-26	2013-09-11	中国科学院广州生物医药与健康研究院	一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类
ES2704986T3 (es)	2008-10-16	2019-03-21	Celator Pharmaceuticals Inc	Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
MX2011004824A (es)	2008-11-07	2012-01-12	Triact Therapeutics Inc	Uso de derivados de butano catecólico en terapia contra el cáncer.
WO2010065444A1 (en) *	2008-12-01	2010-06-10	University Of Central Florida Research Foundation, Inc.	Drug composition cytotoxic for pancreatic cancer cells
HRP20131106T1 (hr)	2008-12-18	2013-12-20	Novartis Ag	Hemifumaratna sol od 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
CN102256941A (zh)	2008-12-18	2011-11-23	诺瓦提斯公司	新的盐
AU2009327405A1 (en)	2008-12-18	2011-06-30	Novartis Ag	New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
TW201920110A (zh)	2009-01-16	2019-06-01	美商艾克塞里克斯公司	包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
WO2010083617A1 (en)	2009-01-21	2010-07-29	Oncalis Ag	Pyrazolopyrimidines as protein kinase inhibitors
US20110281917A1 (en)	2009-01-29	2011-11-17	Darrin Stuart	Substituted Benzimidazoles for the Treatment of Astrocytomas
JP2012518598A (ja)	2009-02-25	2012-08-16	Ｍｓｄ株式会社	ピリミドピリミドインダゾール誘導体
EP2400985A2 (en)	2009-02-25	2012-01-04	OSI Pharmaceuticals, LLC	Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
EP2400990A2 (en)	2009-02-26	2012-01-04	OSI Pharmaceuticals, LLC	In situ methods for monitoring the emt status of tumor cells in vivo
US8465912B2 (en)	2009-02-27	2013-06-18	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2403339B1 (en)	2009-03-06	2017-01-18	Merck Sharp & Dohme Corp.	Combination cancer therapy with an akt inhibitor and other anticancer agents
WO2010107968A1 (en)	2009-03-18	2010-09-23	Osi Pharmaceuticals, Inc.	Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
EP2408817B1 (en)	2009-03-20	2016-03-16	F.Hoffmann-La Roche Ag	Bispecific anti-her antibodies
SG174382A1 (en)	2009-04-06	2011-11-28	Wyeth Llc	Treatment regimen utilizing neratinib for breast cancer
US8530492B2 (en)	2009-04-17	2013-09-10	Nektar Therapeutics	Oligomer-protein tyrosine kinase inhibitor conjugates
KR101360725B1 (ko)	2009-06-26	2014-02-07	노파르티스 아게	Ｃｙｐ17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
LT2451445T (lt)	2009-07-06	2019-06-25	Boehringer Ingelheim International Gmbh	Bibw2992, jo druskų ir kietų farmacinių kompozicijų, apimančių šį aktyvųjį ingredientą, džiovinimo būdas
US9050341B2 (en) *	2009-07-14	2015-06-09	Natco Pharma Limited	Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
US9345661B2 (en)	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EA201200260A1 (ru)	2009-08-12	2012-09-28	Новартис Аг	Гетероциклические гидразоны и их применение для лечения рака и воспаления
AU2010284254B2 (en)	2009-08-17	2015-09-17	Intellikine, Llc	Heterocyclic compounds and uses thereof
ES2564797T3 (es)	2009-08-19	2016-03-29	Eisai R&D Management Co., Ltd.	Composición farmacéutica con contenido en un derivado de quinolina
EA201200318A1 (ru)	2009-08-20	2012-09-28	Новартис Аг	Гетероциклические оксимы
JP2013503129A (ja)	2009-08-26	2013-01-31	ノバルティスアーゲー	テトラ−置換ヘテロアリール化合物ならびにｍｄｍ２および／またはｍｄｍ４モジュレーターとしてのそれらの使用
AU2010294209A1 (en)	2009-09-10	2012-03-29	Irm Llc	Ether derivatives of bicyclic heteroaryls
US20120220594A1 (en)	2009-10-30	2012-08-30	Bristol-Meyers Squibb Company	Methods for treating cancer in patients having igf-1r inhibitor resistance
EP2496575B1 (en)	2009-11-04	2014-04-30	Novartis AG	Heterocyclic sulfonamide derivatives useful as mek inhibitors
JP2013510871A (ja)	2009-11-12	2013-03-28	ジェネンテック，インコーポレイテッド	樹状突起棘の密度を促す方法
WO2011058164A1 (en)	2009-11-13	2011-05-19	Pangaea Biotech, S.A.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EA201200617A1 (ru)	2009-11-23	2012-11-30	Серулин Фарма Инк.	Полимеры на основе циклодекстрина для доставки лекарственных средств
CN102712648A (zh)	2009-11-25	2012-10-03	诺瓦提斯公司	双环杂芳基的与苯稠合的6元含氧杂环衍生物
WO2011069104A2 (en)	2009-12-04	2011-06-09	Genentech, Inc.	Multispecific antibodies, antibody analogs, compositions, and methods
ES2484171T3 (es)	2009-12-08	2014-08-11	Novartis Ag	Derivados de sulfonamidas heterocíclicas
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
CU24130B1 (es)	2009-12-22	2015-09-29	Novartis Ag	Isoquinolinonas y quinazolinonas sustituidas
WO2011086053A1 (en)	2010-01-12	2011-07-21	F. Hoffmann-La Roche Ag	Tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2011090940A1 (en)	2010-01-19	2011-07-28	Cerulean Pharma Inc.	Cyclodextrin-based polymers for therapeutic delivery
CN102146060B (zh) *	2010-02-09	2013-07-03	陕西师范大学	制备吉非替尼及其中间体的方法
SG183333A1 (en)	2010-02-18	2012-09-27	Genentech Inc	Neuregulin antagonists and use thereof in treating cancer
AU2011222867B2 (en)	2010-03-04	2014-03-06	Annika Algars	Method for selecting patients for treatment with an EGFR inhibitor
RU2012141536A (ru)	2010-03-17	2014-04-27	Ф. Хоффманн-Ля Рош Аг	Имидазопиридины, композиции и способы применения
US20110237686A1 (en)	2010-03-26	2011-09-29	Cerulean Pharma Inc	Formulations and methods of use
CA2794708C (en)	2010-03-29	2021-11-16	Zymeworks Inc.	Antibodies with enhanced or suppressed effector function
TWI406853B (zh) *	2010-04-07	2013-09-01	Dev Center Biotechnology	Ｅｇｆｒ與ｖｅｇｆｒ－２雙重抑制劑及其用途與製法
CN103038643A (zh)	2010-04-16	2013-04-10	基因泰克公司	作为pi3k/akt激酶途径抑制剂效能的预测性生物标记的foxo3a
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
CN102947274A (zh)	2010-06-17	2013-02-27	诺瓦提斯公司	联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
JP2013532149A (ja)	2010-06-17	2013-08-15	ノバルティスアーゲー	ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
WO2011161217A2 (en)	2010-06-23	2011-12-29	Palacký University in Olomouc	Targeting of vegfr2
RU2560683C2 (ru)	2010-06-25	2015-08-20	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
UA112517C2 (uk)	2010-07-06	2016-09-26	Новартіс Аг	Тетрагідропіридопіримідинові похідні
AR082418A1 (es)	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
KR20130103734A (ko)	2010-08-31	2013-09-24	제넨테크, 인크.	바이오마커 및 치료 방법
BR112013006016A2 (pt)	2010-09-15	2016-06-07	Hoffmann La Roche	compostos de azabenzotiazol, composições e métodos de uso
US8946260B2 (en)	2010-09-16	2015-02-03	Novartis Ag	17α-hydroxylase/C17,20-lyase inhibitors
EA201390421A1 (ru)	2010-09-22	2013-09-30	Арена Фармасьютикалз, Инк.	Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
EP2637692A4 (en)	2010-11-12	2014-09-10	Scott & White Healthcare	ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
BR112013011520A2 (pt)	2010-11-19	2019-09-24	Hoffmann La Roche	pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
AU2011333738A1 (en)	2010-11-24	2013-07-11	Glaxo Group Limited	Multispecific antigen binding proteins targeting HGF
MX2013007336A (es)	2010-12-21	2013-08-01	Novartis Ag	Compuestos de bi-heteroarilo como inhibidores de vps34.
EP2468883A1 (en)	2010-12-22	2012-06-27	Pangaea Biotech S.L.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
WO2012085176A1 (en)	2010-12-23	2012-06-28	F. Hoffmann-La Roche Ag	Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
US9134297B2 (en)	2011-01-11	2015-09-15	Icahn School Of Medicine At Mount Sinai	Method and compositions for treating cancer and related methods
PL2670753T3 (pl)	2011-01-31	2017-05-31	Novartis Ag	Nowe pochodne heterocykliczne
US20130324526A1 (en)	2011-02-10	2013-12-05	Novartis Ag	[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en)	2011-02-23	2012-08-30	Intellikine, Llc	Heterocyclic compounds and uses thereof
EP2492688A1 (en)	2011-02-23	2012-08-29	Pangaea Biotech, S.A.	Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012122058A2 (en)	2011-03-04	2012-09-13	Newgen Therapeutics, Inc.	Alkyne substituted quinazoline compound and methods of use
CN103492390A (zh)	2011-03-08	2014-01-01	诺瓦提斯公司	氟苯基双环杂芳基化合物
JP5832559B2 (ja)	2011-03-10	2015-12-16	オメロスコーポレーション	ｅｘｖｉｖｏにおける加速された抗体進化による抗ＦＮ１４モノクローナル抗体の生成
US9295676B2 (en)	2011-03-17	2016-03-29	The Trustees Of The University Of Pennsylvania	Mutation mimicking compounds that bind to the kinase domain of EGFR
WO2012125913A1 (en)	2011-03-17	2012-09-20	The Trustees Of The University Of Pennsylvania	Methods and use of bifunctional enzyme-building clamp-shaped molecules
WO2012129145A1 (en)	2011-03-18	2012-09-27	OSI Pharmaceuticals, LLC	Nscle combination therapy
MY161199A (en)	2011-03-23	2017-04-14	Amgen Inc	Fused tricyclic dual inhibitors of cdk 4/6 and flt3
MX2013009931A (es)	2011-04-18	2013-10-01	Eisai R&D Man Co Ltd	Agentes terapeuticos contra tumores.
WO2012149014A1 (en)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
GB201106870D0 (en)	2011-04-26	2011-06-01	Univ Belfast	Marker
WO2012149413A1 (en)	2011-04-28	2012-11-01	Novartis Ag	17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
CN102918029B (zh)	2011-05-17	2015-06-17	江苏康缘药业股份有限公司	4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
ES2705950T3 (es)	2011-06-03	2019-03-27	Eisai R&D Man Co Ltd	Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
KR20140034898A (ko)	2011-06-09	2014-03-20	노파르티스 아게	헤테로시클릭 술폰아미드 유도체
US8859535B2 (en)	2011-06-20	2014-10-14	Novartis Ag	Hydroxy substituted isoquinolinone derivatives
EP2721007B1 (en)	2011-06-20	2015-04-29	Novartis AG	Cyclohexyl isoquinolinone compounds
SG195067A1 (en)	2011-06-27	2013-12-30	Novartis Ag	Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
RU2013155695A (ru)	2011-06-30	2015-08-10	Дженентек, Инк.	Препараты антител против с-мет
WO2013007765A1 (en)	2011-07-13	2013-01-17	F. Hoffmann-La Roche Ag	Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013007768A1 (en)	2011-07-13	2013-01-17	F. Hoffmann-La Roche Ag	Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
EP2742067A4 (en)	2011-08-12	2015-03-04	Omeros Corp	MONOCLONAL FZD10 ANTIBODIES AND METHOD FOR THEIR USE
CA2843499A1 (en)	2011-08-12	2013-02-21	F. Hoffmann-La Roche Ag	Indazole compounds, compositions and methods of use
WO2013025939A2 (en)	2011-08-16	2013-02-21	Indiana University Research And Technology Corporation	Compounds and methods for treating cancer by inhibiting the urokinase receptor
US12194002B2 (en)	2011-08-17	2025-01-14	Dennis Brown	Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
CA2842375A1 (en)	2011-08-17	2013-02-21	Erica Jackson	Neuregulin antibodies and uses thereof
RU2614254C2 (ru)	2011-08-31	2017-03-24	Дженентек, Инк.	Диагностические маркеры
EA026655B1 (ru)	2011-09-15	2017-05-31	Новартис Аг	6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
WO2013041539A1 (en)	2011-09-20	2013-03-28	F. Hoffmann-La Roche Ag	Imidazopyridine compounds, compositions and methods of use
CN103012290B (zh) *	2011-09-28	2015-05-13	齐鲁制药有限公司	一种高纯度吉非替尼的制备方法
MX2014003698A (es)	2011-09-30	2014-07-28	Genentech Inc	Marcadores de diagnostico.
WO2013056069A1 (en)	2011-10-13	2013-04-18	Bristol-Myers Squibb Company	Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
PT2771342T (pt)	2011-10-28	2016-08-17	Novartis Ag	Derivados de purina e o seu uso no tratamento de doença
CN103102342B (zh) *	2011-11-14	2014-10-29	广东东阳光药业有限公司	氨基喹唑啉类衍生物及其盐和使用方法
TWI577671B (zh)	2011-11-14	2017-04-11	Sunshine Lake Pharma Co Ltd	Aminoquinazoline derivatives and salts thereof and methods of use thereof
CN103102345B (zh) *	2011-11-14	2015-06-03	广东东阳光药业有限公司	氨基喹唑啉类衍生物及其盐和使用方法
EP2785717B1 (en)	2011-11-29	2016-01-13	Novartis AG	Pyrazolopyrrolidine compounds
CA2857114A1 (en)	2011-11-30	2013-06-06	Genentech, Inc.	Erbb3 mutations in cancer
US9408885B2 (en)	2011-12-01	2016-08-09	Vib Vzw	Combinations of therapeutic agents for treating melanoma
CN103130729B (zh) *	2011-12-05	2015-07-15	齐鲁制药有限公司	一种4-氯代-7-甲氧基喹唑啉-6-醇乙酸酯的制备方法
CN103172576B (zh) *	2011-12-21	2015-08-05	沈阳药科大学	吉非替尼的苹果酸加成盐及其制备和应用
LT2794600T (lt)	2011-12-22	2018-02-26	Novartis Ag	2,3-dihidro-benzo[1,4]oksazino dariniai ir giminingi junginiai kaip fosfoinozitido-3 kinazės (pi3k) inhibitoriai, skirti gydymui, pavyzdžiui, reumatoidinio artrito
WO2013093850A1 (en)	2011-12-22	2013-06-27	Novartis Ag	Quinoline derivatives
US20140357633A1 (en)	2011-12-23	2014-12-04	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
EA201491259A1 (ru)	2011-12-23	2014-11-28	Новартис Аг	Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
EA201491265A1 (ru)	2011-12-23	2014-11-28	Новартис Аг	Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
US20130178520A1 (en)	2011-12-23	2013-07-11	Duke University	Methods of treatment using arylcyclopropylamine compounds
EA201491268A1 (ru)	2011-12-23	2014-11-28	Новартис Аг	Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
KR20140104047A (ko)	2011-12-23	2014-08-27	노파르티스 아게	Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
UY34591A (es)	2012-01-26	2013-09-02	Novartis Ag	Compuestos de imidazopirrolidinona
CA2863287A1 (en)	2012-01-31	2013-08-08	Smithkline Beecham (Cork) Limited	Method of treating cancer
CA2866612C (en)	2012-03-08	2018-01-16	Halozyme, Inc.	Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
AR090263A1 (es)	2012-03-08	2014-10-29	Hoffmann La Roche	Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US9193718B2 (en)	2012-03-26	2015-11-24	Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences	Quinazoline derivative and application thereof
CN104220457A (zh)	2012-03-27	2014-12-17	霍夫曼-拉罗奇有限公司	涉及her3抑制剂的诊断和治疗
US20150297604A1 (en)	2012-04-03	2015-10-22	Novartis Ag	Combination Products with Tyrosine Kinase Inhibitors and their Use
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
US10213432B2 (en)	2012-05-16	2019-02-26	Novartis Ag	Dosage regimen for a PI-3 kinase inhibitor
WO2013175417A1 (en)	2012-05-24	2013-11-28	Novartis Ag	Pyrrolopyrrolidinone compounds
KR101457453B1 (ko) *	2012-05-31	2014-11-04	주식회사 종근당	게피티닙의 제조방법 및 이의 제조에 사용되는 중간체
US9789193B2 (en)	2012-06-15	2017-10-17	The Brigham And Women's Hospital, Inc.	Compositions for treating cancer and methods for making the same
WO2013190089A1 (en)	2012-06-21	2013-12-27	Pangaea Biotech, S.L.	Molecular biomarkers for predicting outcome in lung cancer
WO2014016848A2 (en)	2012-07-24	2014-01-30	Laurus Labs Private Limited	Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
US9738643B2 (en)	2012-08-06	2017-08-22	Duke University	Substituted indazoles for targeting Hsp90
US9505749B2 (en)	2012-08-29	2016-11-29	Amgen Inc.	Quinazolinone compounds and derivatives thereof
EP3919069A1 (en)	2012-11-05	2021-12-08	Dana-Farber Cancer Institute, Inc.	Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
TW201422625A (zh)	2012-11-26	2014-06-16	Novartis Ag	二氫－吡啶并－□衍生物之固體形式
WO2014098176A1 (ja)	2012-12-21	2014-06-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	キノリン誘導体のアモルファス及びその製造方法
CN103073509A (zh) *	2012-12-31	2013-05-01	广东先强药业有限公司	一类喹唑啉衍生物的制备方法
CN103910690A (zh) *	2013-01-06	2014-07-09	上海科胜药物研发有限公司	一种吉非替尼新晶型及其制备方法
US20150329524A1 (en)	2013-01-10	2015-11-19	Glaxosmithkline Intellectual Property (No.2) Limited	Fatty acid synthase inhibitors
WO2014115080A1 (en)	2013-01-22	2014-07-31	Novartis Ag	Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en)	2013-01-22	2016-08-02	Novartis Ag	Substituted purinone compounds
CN104968200B (zh)	2013-02-01	2018-03-06	维尔斯达医疗公司	具有抗炎、抗真菌、抗寄生物和抗癌活性的胺化合物
WO2014128612A1 (en)	2013-02-20	2014-08-28	Novartis Ag	Quinazolin-4-one derivatives
MX374929B (es)	2013-02-20	2025-03-06	Novartis Ag	RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
CN104994879A (zh)	2013-02-22	2015-10-21	霍夫曼-拉罗奇有限公司	治疗癌症和预防药物抗性的方法
WO2014134202A1 (en)	2013-02-26	2014-09-04	Triact Therapeutics, Inc.	Cancer therapy
US9468681B2 (en)	2013-03-01	2016-10-18	California Institute Of Technology	Targeted nanoparticles
BR112015020787B1 (pt)	2013-03-06	2022-12-06	Astrazeneca Ab	Compostos 4-(substituído-anilino)-6-o-(substituídopiperizina-carbonil)quinazolínicos, seus sais, composição farmacêutica, uso e combinação
KR20150123250A (ko)	2013-03-06	2015-11-03	제넨테크, 인크.	암 약물 내성의 치료 및 예방 방법
BR112015022545A2 (pt)	2013-03-13	2017-07-18	Constellation Pharmaceuticals Inc	compostos de pirazolo e os usos disso
WO2014153030A2 (en)	2013-03-14	2014-09-25	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
AU2014236820B2 (en)	2013-03-14	2018-08-02	Sumitomo Pharma Oncology, Inc.	JAK2 and ALK2 inhibitors and methods for their use
WO2014152358A2 (en)	2013-03-14	2014-09-25	Genentech, Inc.	Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
CN105339001A (zh)	2013-03-15	2016-02-17	基因泰克公司	治疗癌症和预防癌症耐药性的方法
CN105246482A (zh)	2013-03-15	2016-01-13	因特利凯有限责任公司	激酶抑制剂的组合及其用途
US20160051556A1 (en)	2013-03-21	2016-02-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
WO2014147631A1 (en)	2013-03-22	2014-09-25	Natco Pharma Limited	Formulation comprising gefitinib as oral suspension
WO2014155268A2 (en)	2013-03-25	2014-10-02	Novartis Ag	Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
RU2658601C2 (ru)	2013-05-14	2018-06-21	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
US20150018376A1 (en)	2013-05-17	2015-01-15	Novartis Ag	Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
CN103304491A (zh) *	2013-06-17	2013-09-18	连云港盛和生物科技有限公司	一种吉非替尼的制备方法
KR20150001936A (ko) *	2013-06-28	2015-01-07	제일약품주식회사	게피티닙의 신규한 결정형 및 이의 제조방법
UY35675A (es)	2013-07-24	2015-02-27	Novartis Ag	Derivados sustituidos de quinazolin-4-ona
HK1226058A1 (zh) *	2013-08-02	2017-09-22	亚尼塔公司	单独地或与其它试剂联合地使用axl/cmet抑制剂治疗多种癌症的方法
US9227969B2 (en)	2013-08-14	2016-01-05	Novartis Ag	Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
WO2015022664A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
MX2016002794A (es)	2013-09-05	2016-09-13	Genentech Inc	Compuestos antiproliferativos.
CA2923667A1 (en)	2013-09-09	2015-03-12	Triact Therapeutics, Inc.	Cancer therapy
CA2922562A1 (en)	2013-09-12	2015-03-19	Halozyme, Inc.	Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
AR097661A1 (es)	2013-09-17	2016-04-06	Obi Pharma Inc	Composiciones de una vacuna de carbohidratos para inducir respuestas inmunológicas y sus usos en el tratamiento del cáncer
AU2014321419B2 (en)	2013-09-22	2017-06-15	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine compounds and methods of use
CN104513253A (zh) *	2013-10-01	2015-04-15	南京波尔泰药业科技有限公司	用于治疗增殖性疾病的大环化合物
TW201605857A (zh)	2013-10-03	2016-02-16	赫孚孟拉羅股份公司	Ｃｄｋ８之醫療性抑制劑及其用途
TW201940514A (zh)	2013-10-18	2019-10-16	美商建南德克公司	抗-rspo抗體及使用方法
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
MX378409B (es)	2013-12-06	2025-03-10	Novartis Ag	Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.
CA2933883A1 (en)	2013-12-17	2015-06-25	Genentech, Inc.	Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
EP3527587A1 (en)	2013-12-17	2019-08-21	F. Hoffmann-La Roche AG	Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US20160361309A1 (en)	2014-02-26	2016-12-15	Glaxosmithkline Intellectual Property (No.2) Limited	Methods of treating cancer patients responding to ezh2 inhibitor gsk126
MX2016012285A (es)	2014-03-24	2017-01-23	Genentech Inc	Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
US10000469B2 (en)	2014-03-25	2018-06-19	Duke University	Heat shock protein 70 (hsp-70) receptor ligands
WO2015145388A2 (en)	2014-03-27	2015-10-01	Novartis Ag	Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP3122729A4 (en)	2014-03-28	2017-11-15	Calitor Sciences, LLC	Substituted heteroaryl compounds and methods of use
AU2015241038A1 (en)	2014-03-31	2016-10-13	Genentech, Inc.	Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
CN106103486B (zh)	2014-03-31	2020-04-21	豪夫迈·罗氏有限公司	抗ox40抗体和使用方法
RU2016140160A (ru)	2014-04-03	2018-05-07	Инвиктус Онколоджи Пвт. Лтд.	Супрамолекулярные комбинаторные лекарственные средства
US20170027940A1 (en)	2014-04-10	2017-02-02	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015170345A1 (en)	2014-05-09	2015-11-12	Council Of Scientific & Industrial Research	Pharmaceutical cocrystals of gefitinib
RU2577518C2 (ru) *	2014-06-02	2016-03-20	Олег Ростиславович Михайлов	КРИСТАЛЛИЧЕСКАЯ БЕЗВОДНАЯ γ-МОДИФИКАЦИЯ 4-(3'-ХЛОР-4'-ФТОРАНИЛИНО)-7-МЕТОКСИ-6-(3-МОРФОЛИНОПРОПОКСИ)ХИНАЗОЛИНА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105377820B (zh)	2014-06-10	2020-02-07	神隆医药（常熟）有限公司	制备喹唑啉衍生物的方法
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
JP6526789B2 (ja)	2014-07-31	2019-06-05	ノバルティスアーゲー	組み合わせ療法
ES2926687T3 (es)	2014-08-28	2022-10-27	Eisai R&D Man Co Ltd	Derivado de quinolina muy puro y método para su producción
CN107074823B (zh)	2014-09-05	2021-05-04	基因泰克公司	治疗性化合物及其用途
TWI567063B (zh) *	2014-09-05	2017-01-21	國立交通大學	用於促進癌細胞凋亡的化合物、其醫藥組成物及其用途
JP2017529358A (ja)	2014-09-19	2017-10-05	ジェネンテック，インコーポレイテッド	がんの処置のためのｃｂｐ／ｅｐ３００阻害剤およびｂｅｔ阻害剤の使用
EP3204379B1 (en)	2014-10-10	2019-03-06	Genentech, Inc.	Pyrrolidine amide compounds as histone demethylase inhibitors
EP3206717B1 (en)	2014-10-17	2020-11-25	Novartis AG	Combination of ceritinib with an egfr inhibitor
MX2017005751A (es)	2014-11-03	2018-04-10	Genentech Inc	Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
CN106796235B (zh)	2014-11-03	2021-01-29	豪夫迈·罗氏有限公司	用于检测t细胞免疫子集的测定法及其使用方法
BR112017008628A2 (pt)	2014-11-06	2018-01-30	Genentech Inc	terapia de combinação compreendendo agonistas de ligação a ox40 e inibidores de tigit
MA40940A (fr)	2014-11-10	2017-09-19	Constellation Pharmaceuticals Inc	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3218376B1 (en)	2014-11-10	2019-12-25	Genentech, Inc.	Bromodomain inhibitors and uses thereof
MA40943A (fr)	2014-11-10	2017-09-19	Constellation Pharmaceuticals Inc	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
CA2967368A1 (en)	2014-11-17	2016-05-26	Genentech, Inc.	Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN107531690B (zh)	2014-11-27	2020-11-06	基因泰克公司	用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
KR102138415B1 (ko)	2014-12-04	2020-07-27	데루타-후라이 화마 가부시키가이샤	신규 peg 유도체
US20180000827A1 (en)	2014-12-19	2018-01-04	Synthon B.V.	Pharmaceutical composition comprising gefitinib
WO2016106340A2 (en)	2014-12-23	2016-06-30	Genentech, Inc.	Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
CN107223163A (zh)	2014-12-24	2017-09-29	豪夫迈·罗氏有限公司	用于膀胱癌症的治疗，诊断和预后方法
EP3240908A2 (en)	2014-12-30	2017-11-08	F. Hoffmann-La Roche AG	Methods and compositions for prognosis and treatment of cancers
EP4445956A3 (en)	2015-01-06	2024-12-04	Arena Pharmaceuticals, Inc.	Compound for use in treating conditions related to the s1p1 receptor
ES2887474T3 (es)	2015-01-08	2021-12-22	Univ Leland Stanford Junior	Factores y células que proporcionan inducción de hueso, médula ósea y cartílago
JP6659703B2 (ja)	2015-01-09	2020-03-04	ジェネンテック，インコーポレイテッド	ピリダジノン誘導体および癌の処置におけるそれらの使用
WO2016112251A1 (en)	2015-01-09	2016-07-14	Genentech, Inc.	4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
WO2016112284A1 (en)	2015-01-09	2016-07-14	Genentech, Inc.	(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
KR101635724B1 (ko) *	2015-01-28	2016-07-05	일동제약주식회사	게피티닙의 개선된 제조방법
MA41414A (fr)	2015-01-28	2017-12-05	Centre Nat Rech Scient	Protéines de liaison agonistes d' icos
EP3250571B1 (en)	2015-01-29	2022-11-30	Genentech, Inc.	Therapeutic compounds and uses thereof
EP3250552B1 (en)	2015-01-30	2019-03-27	Genentech, Inc.	Therapeutic compounds and uses thereof
MA41598A (fr)	2015-02-25	2018-01-02	Constellation Pharmaceuticals Inc	Composés thérapeutiques de pyridazine et leurs utilisations
RS65049B1 (sr)	2015-02-25	2024-02-29	Eisai R&D Man Co Ltd	Metoda za suzbijanje gorčine derivata kinolina
AU2015384801B2 (en)	2015-03-04	2022-01-06	Eisai R&D Management Co., Ltd.	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
ES2775614T3 (es) *	2015-03-20	2020-07-27	Chai Tai Tianqing Pharmaceutical Group Co Ltd	Sales de derivado de quinazolina y método de preparación de las mismas
MX2017012805A (es)	2015-04-07	2018-04-11	Genentech Inc	Complejo de unión a antígenos con actividad agonista y métodos de uso.
AU2016262074A1 (en)	2015-05-12	2017-11-09	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
MX392671B (es)	2015-05-29	2025-03-24	Genentech Inc	Antagonistas de unión a pd-l1 y usos de los mismos para el tratamiento de cáncer
KR20180025888A (ko)	2015-06-08	2018-03-09	제넨테크, 인크.	항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
AU2016274585A1 (en)	2015-06-08	2017-12-14	Genentech, Inc.	Methods of treating cancer using anti-OX40 antibodies
CA2988707C (en)	2015-06-16	2023-10-10	Eisai R&D Management Co., Ltd.	Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
KR102689256B1 (ko)	2015-06-17	2024-07-30	제넨테크, 인크.	Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
PL3310760T3 (pl)	2015-06-22	2023-03-06	Arena Pharmaceuticals, Inc.	Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
WO2017003668A1 (en)	2015-07-01	2017-01-05	California Institute Of Technology	Cationic mucic acid polymer-based delivery systems
WO2017025871A1 (en)	2015-08-07	2017-02-16	Glaxosmithkline Intellectual Property Development Limited	Combination therapy comprising anti ctla-4 antibodies
ES2887426T3 (es)	2015-08-20	2021-12-22	Eisai R&D Man Co Ltd	Lenvatinib combinado con etopósido e ifosfamida para su uso en el tratamiento de un tumor
ES2862727T3 (es)	2015-08-26	2021-10-07	Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio	Compuestos tricíclicos condensados como inhibidores de proteínas quinasas
HK1256912A1 (zh)	2015-09-04	2019-10-04	台湾浩鼎生技股份有限公司	聚糖阵列以及使用方法
EP3347097B1 (en)	2015-09-11	2021-02-24	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
GB201516905D0 (en)	2015-09-24	2015-11-11	Stratified Medical Ltd	Treatment of Neurodegenerative diseases
NZ739750A (en)	2015-09-25	2019-11-29	Genentech Inc	Anti-tigit antibodies and methods of use
CN105250228B (zh) *	2015-10-12	2017-10-24	山东罗欣药业集团股份有限公司	一种吉非替尼的片剂及其原料的制备方法
JP2018532750A (ja)	2015-11-02	2018-11-08	ノバルティスアーゲー	ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
CA3006934A1 (en)	2015-12-01	2017-06-08	Glaxosmithkline Intellectual Property Development Limited	Combination of antibodies targeting bcma, pd-1 and ox40 in cancer treatments and uses therof
AU2016369528B2 (en)	2015-12-16	2021-04-22	Genentech, Inc.	Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
WO2017114735A1 (en)	2015-12-30	2017-07-06	Synthon B.V.	Process for making crystalline form a of gefitinib
CN105503748A (zh) *	2015-12-31	2016-04-20	哈药集团技术中心	一种吉非替尼的制备方法
WO2017118675A1 (en)	2016-01-08	2017-07-13	F. Hoffmann-La Roche Ag	Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
EP4155415A1 (en)	2016-02-29	2023-03-29	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
US10980894B2 (en)	2016-03-29	2021-04-20	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
TWI780045B (zh)	2016-03-29	2022-10-11	台灣浩鼎生技股份有限公司	抗體、醫藥組合物及方法
EP3865511A1 (en)	2016-04-14	2021-08-18	F. Hoffmann-La Roche AG	Anti-rspo3 antibodies and methods of use
EP3443120A2 (en)	2016-04-15	2019-02-20	H. Hoffnabb-La Roche Ag	Methods for monitoring and treating cancer
PL3443350T3 (pl)	2016-04-15	2021-05-31	F. Hoffmann-La Roche Ag	Sposoby monitorowania i leczenia nowotworu
KR20180134347A (ko)	2016-04-15	2018-12-18	제넨테크, 인크.	암의 진단 및 치료 방법
WO2017184956A1 (en)	2016-04-22	2017-10-26	Duke University	Compounds and methods for targeting hsp90
RU2018140976A (ru)	2016-04-22	2020-05-22	Оби Фарма, Инк.	Иммунотерапия рака путем иммунной активации или иммунной модуляции через антигены серии globo
US20190151346A1 (en)	2016-05-10	2019-05-23	INSERM (Institute National de la Santé et de la Recherche Médicale)	Combinations therapies for the treatment of cancer
KR101796684B1 (ko) *	2016-05-19	2017-11-10	건국대학교 산학협력단	케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
WO2017205536A2 (en)	2016-05-24	2017-11-30	Genentech, Inc.	Therapeutic compounds and uses thereof
MA45146A (fr)	2016-05-24	2021-03-24	Constellation Pharmaceuticals Inc	Dérivés de pyrazolopyridine pour le traitement du cancer
CN106045980B (zh) *	2016-06-03	2017-11-03	江苏开放大学	一种喹唑啉衍生物及其制备方法
EP4371570A3 (en)	2016-06-08	2024-07-17	Xencor, Inc.	Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
US20200129519A1 (en)	2016-06-08	2020-04-30	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
US11642400B2 (en)	2016-07-27	2023-05-09	Obi Pharma, Inc.	Immunogenic/therapeutic glycan compositions and uses thereof
KR102528998B1 (ko)	2016-07-29	2023-05-03	오비아이 파머 인코퍼레이티드	인간 항체, 제약 조성물 및 방법
WO2018025221A1 (en)	2016-08-04	2018-02-08	Glaxosmithkline Intellectual Property Development Limited	Anti-icos and anti-pd-1 antibody combination therapy
JP2019530434A (ja)	2016-08-05	2019-10-24	ジェネンテック，インコーポレイテッド	アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
CN109476748B (zh)	2016-08-08	2023-05-23	豪夫迈·罗氏有限公司	用于癌症的治疗和诊断方法
WO2018039203A1 (en)	2016-08-23	2018-03-01	Oncopep, Inc.	Peptide vaccines and durvalumab for treating multiple myeloma
WO2018039205A1 (en)	2016-08-23	2018-03-01	Oncopep, Inc.	Peptide vaccines and durvalumab for treating breast cancer
CN106432202B (zh) *	2016-09-22	2019-04-02	郑州大学第一附属医院	喹唑啉类衍生物及其应用
WO2018060833A1 (en)	2016-09-27	2018-04-05	Novartis Ag	Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018064076A1 (en)	2016-09-27	2018-04-05	Cero Therapeutics, Inc.	Chimeric engulfment receptor molecules
US10927083B2 (en)	2016-09-29	2021-02-23	Duke University	Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
US10207998B2 (en)	2016-09-29	2019-02-19	Duke University	Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
CN110418851A (zh)	2016-10-06	2019-11-05	基因泰克公司	癌症的治疗和诊断方法
WO2018078143A1 (en)	2016-10-28	2018-05-03	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
CN110267678A (zh)	2016-10-29	2019-09-20	霍夫曼-拉罗奇有限公司	抗mic抗体和使用方法
KR20190077103A (ko)	2016-11-21	2019-07-02	오비아이 파머 인코퍼레이티드	접합된 생물학적 분자, 제약 조성물 및 방법
KR20230150408A (ko)	2016-12-22	2023-10-30	암젠 인크	폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체
JP6581320B2 (ja)	2017-02-08	2019-09-25	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療用医薬組成物
AU2018228873A1 (en)	2017-03-01	2019-08-29	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
US9980967B1 (en)	2017-03-16	2018-05-29	National Chiao Tung University	Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
BR112019021411A2 (pt)	2017-04-13	2020-05-05	Hoffmann La Roche	métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
RU2019134940A (ru)	2017-05-16	2021-06-16	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Лечение гепатоцеллюлярной карциномы
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
IL271888B2 (en)	2017-07-21	2024-09-01	Genentech Inc	Therapeutic and diagnostic methods for cancer
AU2018316343B2 (en)	2017-08-11	2025-06-12	Genentech, Inc.	Anti-CD8 antibodies and uses thereof
JP7530829B2 (ja)	2017-09-08	2024-08-08	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	がんの診断及び治療方法
AU2018329920B2 (en)	2017-09-08	2022-12-01	Amgen Inc.	Inhibitors of KRAS G12C and methods of using the same
KR20200100598A (ko)	2017-09-26	2020-08-26	세로 테라퓨틱스, 인코포레이티드	키메라 포식작용 수용체 분자 및 사용 방법
WO2019083960A1 (en)	2017-10-24	2019-05-02	Oncopep, Inc.	PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
AU2018353984A1 (en)	2017-10-24	2020-05-07	Oncopep, Inc.	Peptide vaccines and pembrolizumab for treating breast cancer
WO2019084395A1 (en)	2017-10-27	2019-05-02	University Of Virginia Patent Foundation	COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
CN109721552B (zh) *	2017-10-30	2022-09-20	上海北卡医药技术有限公司	一种吉非替尼的制备方法
KR20200075860A (ko)	2017-11-06	2020-06-26	제넨테크, 인크.	암의 진단 및 치료 방법
US10683297B2 (en)	2017-11-19	2020-06-16	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
JP2021506974A (ja)	2017-12-18	2021-02-22	スターングリーン、インク．	チロシンキナーゼ阻害剤として有用なピリミジン化合物
JP7021356B2 (ja)	2017-12-21	2022-02-16	ヘフェイインスティテューツオブフィジカルサイエンス，チャイニーズアカデミーオブサイエンシーズ	ピリミジン誘導体系キナーゼ阻害剤類
SG11202006441SA (en)	2018-01-15	2020-08-28	Epiaxis Therapeutics Pty Ltd	Agents and methods for predicting response to therapy
US10751339B2 (en)	2018-01-20	2020-08-25	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine compounds and methods of use
US11673897B2 (en)	2018-01-26	2023-06-13	Exelixis, Inc.	Compounds for the treatment of kinase-dependent disorders
CR20200355A (es)	2018-01-26	2021-02-22	Exelixis Inc	Compuestos para el tratamiento de trastornos dependientes de cinasas
SMT202500395T1 (it)	2018-01-26	2025-11-10	Exelixis Inc	Composti per il trattamento di disordini chinasi-dipendenti
JP7391027B2 (ja)	2018-02-26	2023-12-04	ジェネンテック，インコーポレイテッド	抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体による治療のための投薬
US12291557B2 (en)	2018-03-28	2025-05-06	Cero Therapeutics Holdings, Inc.	Chimeric TIM4 receptors and uses thereof
WO2019191340A1 (en)	2018-03-28	2019-10-03	Cero Therapeutics, Inc.	Cellular immunotherapy compositions and uses thereof
MX2020010235A (es)	2018-03-28	2020-10-28	Cero Therapeutics Inc	Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
WO2019195753A1 (en) *	2018-04-05	2019-10-10	Tolero Pharmaceuticals, Inc.	Axl kinase inhibitors and use of the same
AU2019262599B2 (en)	2018-05-04	2023-10-12	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
MA52501A (fr)	2018-05-04	2021-03-10	Amgen Inc	Inhibiteurs de kras g12c et leurs procédés d'utilisation
CN108395410A (zh) *	2018-05-09	2018-08-14	日照市普达医药科技有限公司	一种苯胺喹唑啉化合物及其在抗肿瘤药物中的应用
MA52564A (fr)	2018-05-10	2021-03-17	Amgen Inc	Inhibiteurs de kras g12c pour le traitement du cancer
AU2019275404A1 (en)	2018-05-21	2020-12-03	Bruker Spatial Biology, Inc.	Molecular gene signatures and methods of using same
CA3102279A1 (en)	2018-06-01	2019-12-05	Cornell University	Combination therapy for pi3k-associated disease or disorder
EP3802535B1 (en)	2018-06-01	2022-12-14	Amgen, Inc	Kras g12c inhibitors and methods of using the same
CA3102136A1 (en)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
AU2019284472B2 (en)	2018-06-11	2024-05-30	Amgen Inc.	KRAS G12C inhibitors for treating cancer
US11285156B2 (en)	2018-06-12	2022-03-29	Amgen Inc.	Substituted piperazines as KRAS G12C inhibitors
JP7483193B2 (ja)	2018-06-13	2024-05-15	カリフォルニア・インスティテュート・オブ・テクノロジー	血脳バリアを越えるためのナノ粒子とそれを用いた治療法
JP7399895B2 (ja)	2018-06-23	2023-12-18	ジェネンテック，インコーポレイテッド	Ｐｄ－１軸結合拮抗薬、白金剤、およびトポイソメラーゼｉｉ阻害剤で肺癌を治療する方法
TW202504930A (zh)	2018-06-27	2025-02-01	台灣浩鼎生技股份有限公司	用於糖蛋白工程的糖苷合成酶變體及其使用方法
BR112021000673A2 (pt)	2018-07-18	2021-04-20	Genentech, Inc.	métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
WO2020023628A1 (en)	2018-07-24	2020-01-30	Hygia Pharmaceuticals, Llc	Compounds, derivatives, and analogs for cancer
CN112512597A (zh)	2018-07-26	2021-03-16	大日本住友制药肿瘤公司	用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
CN112805267B (zh)	2018-09-03	2024-03-08	豪夫迈·罗氏有限公司	用作tead调节剂的甲酰胺和磺酰胺衍生物
CN112955747A (zh)	2018-09-19	2021-06-11	豪夫迈·罗氏有限公司	膀胱癌的治疗和诊断方法
JP7475336B2 (ja)	2018-09-21	2024-04-26	ジェネンテック，インコーポレイテッド	トリプルネガティブ乳癌のための診断方法
JP2022512584A (ja)	2018-10-04	2022-02-07	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	角皮症を処置するためのｅｇｆｒインヒビター
AU2019362972A1 (en)	2018-10-17	2021-05-20	The University Of Queensland	Epigenetic biomarker and uses therefor
AU2019361983A1 (en)	2018-10-18	2021-05-20	Genentech, Inc.	Diagnostic and therapeutic methods for sarcomatoid kidney cancer
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MX2021005700A (es)	2018-11-19	2021-07-07	Amgen Inc	Inhibidores de kras g12c y metodos de uso de los mismos.
WO2020131627A1 (en)	2018-12-19	2020-06-25	Array Biopharma Inc.	Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
JP2022515197A (ja)	2018-12-19	2022-02-17	アレイバイオファーマインコーポレイテッド	がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
CA3123042A1 (en)	2018-12-20	2020-06-25	Amgen Inc.	Kif18a inhibitors
MX419368B (es)	2018-12-20	2025-01-14	Amgen Inc	Heteroarilamidas utiles como inhibidores de kif18a
KR102875569B1 (ko)	2018-12-20	2025-10-23	암젠 인크	Kif18a 억제제
EP3898592B1 (en)	2018-12-20	2024-10-09	Amgen Inc.	Heteroaryl amides useful as kif18a inhibitors
EP3903828A4 (en)	2018-12-21	2022-10-05	Daiichi Sankyo Company, Limited	ANTIBODY-DRUG CONJUGATE AND KINAS INHIBITOR COMBINATION
BR112021014911A2 (pt)	2019-02-01	2021-11-23	Glaxosmithkline Ip Dev Ltd	Belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncer
CN113396230A (zh)	2019-02-08	2021-09-14	豪夫迈·罗氏有限公司	癌症的诊断和治疗方法
BR112021016923A2 (pt)	2019-02-27	2021-11-03	Genentech Inc	Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
JP7520389B2 (ja)	2019-02-27	2024-07-23	エピアクシスセラピューティクスプロプライエタリーリミテッド	Ｔ細胞機能を評価して治療法に対する応答を予測するための方法および薬剤
AU2020232242A1 (en)	2019-03-01	2021-09-09	Revolution Medicines, Inc.	Bicyclic heteroaryl compounds and uses thereof
CN113727758A (zh)	2019-03-01	2021-11-30	锐新医药公司	双环杂环基化合物及其用途
WO2020223233A1 (en)	2019-04-30	2020-11-05	Genentech, Inc.	Prognostic and therapeutic methods for colorectal cancer
MX2021013222A (es)	2019-05-03	2022-01-06	Genentech Inc	Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
CA3140392A1 (en)	2019-05-21	2020-11-26	Amgen Inc.	Solid state forms
BR112021025476A2 (pt)	2019-06-26	2022-10-11	Glaxosmithkline Ip Dev Ltd	Proteínas de ligação à il1rap
CN112300279A (zh)	2019-07-26	2021-02-02	上海复宏汉霖生物技术股份有限公司	针对抗cd73抗体和变体的方法和组合物
ES3051917T3 (en)	2019-08-02	2025-12-30	Amgen Inc	Kif18a inhibitors
US20220281843A1 (en)	2019-08-02	2022-09-08	Amgen Inc.	Kif18a inhibitors
AU2020324406A1 (en)	2019-08-02	2022-03-17	Amgen Inc.	KIF18A inhibitors
CA3147276A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Kif18a inhibitors
TWI873176B (zh)	2019-09-04	2025-02-21	美商建南德克公司	Ｃｄ８結合劑及其用途
WO2021043961A1 (en)	2019-09-06	2021-03-11	Glaxosmithkline Intellectual Property Development Limited	Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021046293A1 (en)	2019-09-06	2021-03-11	Glaxosmithkline Intellectual Property Development Limited	Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
JP2022551422A (ja)	2019-09-26	2022-12-09	エグゼリクシス，インコーポレイテッド	ピリドン化合物およびタンパク質キナーゼの調節における使用の方法
WO2021062085A1 (en)	2019-09-27	2021-04-01	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
US20240058446A1 (en)	2019-10-03	2024-02-22	Cero Therapeutics, Inc.	Chimeric tim4 receptors and uses thereof
AU2020369569A1 (en)	2019-10-24	2022-04-14	Amgen Inc.	Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
EP4051674A1 (en)	2019-10-29	2022-09-07	F. Hoffmann-La Roche AG	Bifunctional compounds for the treatment of cancer
CN120699039A (zh)	2019-11-04	2025-09-26	锐新医药公司	Ras抑制剂
WO2021091982A1 (en)	2019-11-04	2021-05-14	Revolution Medicines, Inc.	Ras inhibitors
BR112022008535A2 (pt)	2019-11-04	2022-08-09	Revolution Medicines Inc	Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
JP2022553803A (ja)	2019-11-06	2022-12-26	ジェネンテック，インコーポレイテッド	血液がんの処置のための診断方法及び治療方法
US20210139517A1 (en)	2019-11-08	2021-05-13	Revolution Medicines, Inc.	Bicyclic heteroaryl compounds and uses thereof
WO2021094379A1 (en)	2019-11-12	2021-05-20	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
KR20220101138A (ko)	2019-11-13	2022-07-19	제넨테크, 인크.	치료적 화합물 및 사용 방법
EP4058465A1 (en)	2019-11-14	2022-09-21	Cohbar Inc.	Cxcr4 antagonist peptides
TW202532412A (zh)	2019-11-14	2025-08-16	美商安進公司	Kras g12c抑制劑化合物之改善的合成
AU2020383535A1 (en)	2019-11-14	2022-05-05	Amgen Inc.	Improved synthesis of KRAS G12C inhibitor compound
JP2023505100A (ja)	2019-11-27	2023-02-08	レボリューションメディシンズインコーポレイテッド	共有ｒａｓ阻害剤及びその使用
PE20221511A1 (es)	2019-12-13	2022-10-04	Genentech Inc	Anticuerpos anti-ly6g6d y metodos de uso
WO2021127404A1 (en)	2019-12-20	2021-06-24	Erasca, Inc.	Tricyclic pyridones and pyrimidones
JP2023509701A (ja)	2020-01-07	2023-03-09	レヴォリューション・メディスンズ，インコーポレイテッド	Ｓｈｐ２阻害剤投薬およびがんを処置する方法
KR20220130190A (ko)	2020-01-20	2022-09-26	아스트라제네카 아베	암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제
IL294800A (en)	2020-01-27	2022-09-01	Genentech Inc	Methods for treatment of cancer with an anti-tigit antagonist antibody
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021152495A1 (en)	2020-01-28	2021-08-05	Glaxosmithkline Intellectual Property Development Limited	Combination treatments and uses and methods thereof
WO2021177980A1 (en)	2020-03-06	2021-09-10	Genentech, Inc.	Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
WO2021185844A1 (en)	2020-03-16	2021-09-23	Pvac Medical Technologies Ltd	Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021233534A1 (en)	2020-05-20	2021-11-25	Pvac Medical Technologies Ltd	Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
EP4122925A4 (en) *	2020-03-17	2024-04-17	Medshine Discovery Inc.	PROTEOLYSIS REGULATOR AND METHOD OF USE
JP2023520515A (ja)	2020-04-03	2023-05-17	ジェネンテック，インコーポレイテッド	がんに対する治療方法及び診断方法
EP4136228A4 (en)	2020-04-15	2024-09-11	California Institute of Technology	THERMAL REGULATION OF T-CELL IMMUNOTHERAPY BY MOLECULAR AND PHYSICAL ACTUATION
CN115885050A (zh)	2020-04-28	2023-03-31	基因泰克公司	用于非小细胞肺癌免疫疗法的方法和组合物
CN118221596A (zh) *	2020-06-15	2024-06-21	山东新时代药业有限公司	一种吉非替尼的有机酸盐
AU2021293038A1 (en)	2020-06-16	2023-02-02	F. Hoffmann-La Roche Ag	Methods and compositions for treating triple-negative breast cancer
KR20230042600A (ko)	2020-06-18	2023-03-28	레볼루션 메디슨즈, 인크.	Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
MX2022015881A (es)	2020-06-18	2023-01-24	Genentech Inc	Tratamiento con anticuerpos anti-tigit y antagonistas de union al eje de pd-1.
EP4172628A1 (en)	2020-06-30	2023-05-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
JP2023531305A (ja)	2020-06-30	2023-07-21	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	術前補助療法後の固形癌患者の再発及び／又は死亡のリスクを予測するための方法。
US11787775B2 (en)	2020-07-24	2023-10-17	Genentech, Inc.	Therapeutic compounds and methods of use
EP4189121A1 (en)	2020-08-03	2023-06-07	Genentech, Inc.	Diagnostic and therapeutic methods for lymphoma
EP4192509A1 (en)	2020-08-05	2023-06-14	Ellipses Pharma Ltd	Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
EP4196612A1 (en)	2020-08-12	2023-06-21	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
WO2022036285A1 (en)	2020-08-14	2022-02-17	Cero Therapeutics, Inc.	Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
WO2022036287A1 (en)	2020-08-14	2022-02-17	Cero Therapeutics, Inc.	Anti-cd72 chimeric receptors and uses thereof
WO2022036265A1 (en)	2020-08-14	2022-02-17	Cero Therapeutics, Inc.	Chimeric tim receptors and uses thereof
WO2022047243A1 (en)	2020-08-27	2022-03-03	Enosi Life Sciences Corp.	Methods and compositions to treat autoimmune diseases and cancer
WO2022047259A1 (en)	2020-08-28	2022-03-03	California Institute Of Technology	Synthetic mammalian signaling circuits for robust cell population control
CA3187757A1 (en)	2020-09-03	2022-03-24	Ethan AHLER	Use of sos1 inhibitors to treat malignancies with shp2 mutations
MX2023003060A (es)	2020-09-15	2023-04-05	Revolution Medicines Inc	Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
MX2023003338A (es)	2020-09-23	2023-06-14	Erasca Inc	Piridonas y pirimidonas tricíclicas.
CA3193952A1 (en)	2020-10-05	2022-04-14	Bernard Martin Fine	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202237638A (zh)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
US20230107642A1 (en)	2020-12-18	2023-04-06	Erasca, Inc.	Tricyclic pyridones and pyrimidones
JP2024501280A (ja)	2020-12-22	2024-01-11	キル・レガー・セラピューティクス・インコーポレーテッド	Ｓｏｓ１阻害剤およびその使用
CN112321814B (zh) *	2020-12-30	2021-03-23	广州初曲科技有限公司	一种吉非替尼艾地苯醌轭合物的制备及用途
KR20230146052A (ko)	2021-02-12	2023-10-18	에프. 호프만-라 로슈 아게	암 치료용 비시클릭 테트라히드로아제핀 유도체
CA3211063A1 (en)	2021-02-19	2022-08-25	Exelixis, Inc.	Pyridone compounds and methods of use
MX2023009910A (es)	2021-02-26	2023-11-09	Kelonia Therapeutics Inc	Vectores lentivirales dirigidos a los linfocitos.
CN118561952A (zh)	2021-05-05	2024-08-30	锐新医药公司	Ras抑制剂
CR20230558A (es)	2021-05-05	2024-01-24	Revolution Medicines Inc	Inhibidores de ras para el tratamiento del cáncer
CN117500811A (zh)	2021-05-05	2024-02-02	锐新医药公司	共价ras抑制剂及其用途
EP4347603A1 (en)	2021-05-25	2024-04-10	Erasca, Inc.	Sulfur-containing heteroaromatic tricyclic kras inhibitors
WO2022266206A1 (en)	2021-06-16	2022-12-22	Erasca, Inc.	Kras inhibitor conjugates
CN113527266A (zh) *	2021-06-23	2021-10-22	上海健康医学院	一种靶向fap的双氧水响应的前药及其制备方法与应用
CN113336742B (zh)	2021-06-29	2022-05-10	山东金吉利新材料有限公司	一种马来酸吡咯替尼中间体的合成方法
AU2022315530A1 (en)	2021-07-20	2024-01-18	Ags Therapeutics Sas	Extracellular vesicles from microalgae, their preparation, and uses
KR20240119868A (ko)	2021-07-28	2024-08-06	세로 테라퓨틱스, 인코포레이티드	키메라 tim4 수용체 및 이의 용도
TW202321261A (zh)	2021-08-10	2023-06-01	美商伊瑞斯卡公司	選擇性ｋｒａｓ抑制劑
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
CN113845485B (zh) *	2021-10-22	2023-03-14	湖南中医药大学	氨基酸衍生物及其制备方法和应用
WO2023097195A1 (en)	2021-11-24	2023-06-01	Genentech, Inc.	Therapeutic indazole compounds and methods of use in the treatment of cancer
JP2024543912A (ja)	2021-11-24	2024-11-26	ジェネンテック，インコーポレイテッド	二環式治療用化合物及びがんの処置における使用方法
EP4448526A1 (en)	2021-12-17	2024-10-23	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
WO2023144127A1 (en)	2022-01-31	2023-08-03	Ags Therapeutics Sas	Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
CN118829629A (zh)	2022-03-07	2024-10-22	美国安进公司	用于制备4-甲基-2-丙-2-基-吡啶-3-甲腈的方法
JP2025510572A (ja)	2022-03-08	2025-04-15	レボリューションメディシンズインコーポレイテッド	免疫不応性肺癌を治療するための方法
US20250205233A1 (en)	2022-03-31	2025-06-26	Astrazeneca Ab	Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
CA3246312A1 (en)	2022-04-01	2023-10-05	Genentech, Inc.	DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
AU2022458320A1 (en)	2022-05-11	2024-11-28	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CA3257760A1 (en)	2022-06-07	2023-12-14	Genentech, Inc.	PROGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
CN119998298A (zh)	2022-06-10	2025-05-13	锐新医药公司	大环ras抑制剂
MA71241A (fr)	2022-06-27	2025-04-30	Astrazeneca Ab	Combinaisons impliquant des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour traiter le cancer
EP4554978A1 (en)	2022-07-13	2025-05-21	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CN119604530A (zh)	2022-07-19	2025-03-11	基因泰克公司	用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
WO2024030441A1 (en)	2022-08-02	2024-02-08	National University Corporation Hokkaido University	Methods of improving cellular therapy with organelle complexes
KR20250038674A (ko)	2022-08-11	2025-03-19	에프. 호프만-라 로슈 아게	바이시클릭 테트라히드로티아제핀 유도체
JP2025526726A (ja)	2022-08-11	2025-08-15	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	二環式テトラヒドロアゼピン誘導体
PE20250876A1 (es)	2022-08-11	2025-03-28	Hoffmann La Roche	Derivados biciclicos de tetrahidrotiazepina
WO2024033457A1 (en)	2022-08-11	2024-02-15	F. Hoffmann-La Roche Ag	Bicyclic tetrahydrothiazepine derivatives
EP4601644A1 (en)	2022-10-14	2025-08-20	Black Diamond Therapeutics, Inc.	Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
JP2025538859A (ja)	2022-10-21	2025-12-02	公益財団法人川崎市産業振興財団	非吸着性またはスーパーステルス小胞
CN121038801A (zh)	2022-10-24	2025-11-28	Ags治疗简易股份公司	来自微藻的细胞外囊泡、它们在鼻内施用时的生物分布及其用途
TW202426505A (zh)	2022-10-25	2024-07-01	美商建南德克公司	癌症之治療及診斷方法
TW202434206A (zh)	2023-02-17	2024-09-01	美商伊瑞斯卡公司	Ｋｒａｓ抑制劑
AU2024241633A1 (en)	2023-03-30	2025-11-06	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
AR132338A1 (es)	2023-04-07	2025-06-18	Revolution Medicines Inc	Inhibidores de ras
WO2024211712A1 (en)	2023-04-07	2024-10-10	Revolution Medicines, Inc.	Condensed macrocyclic compounds as ras inhibitors
TW202448897A (zh)	2023-04-14	2024-12-16	美商銳新醫藥公司	Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
CN121100123A (zh)	2023-04-14	2025-12-09	锐新医药公司	Ras抑制剂的结晶形式
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
AU2024270495A1 (en)	2023-05-05	2025-10-09	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202504641A (zh)	2023-06-08	2025-02-01	美商建南德克公司	用於淋巴瘤之診斷及治療方法的巨噬細胞特徵
WO2025024257A1 (en)	2023-07-21	2025-01-30	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
WO2025034702A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025049277A1 (en)	2023-08-25	2025-03-06	Genentech, Inc.	Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
TW202530228A (zh)	2023-10-12	2025-08-01	美商銳新醫藥公司	Ｒａｓ抑制劑
WO2025137507A1 (en)	2023-12-22	2025-06-26	Regor Pharmaceuticals, Inc.	Sos1 inhibitors and uses thereof
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
WO2025176843A1 (en)	2024-02-21	2025-08-28	Ags Therapeutics Sas	Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
WO2025240847A1 (en)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Ras inhibitors
US20250375445A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3266990A (en) *	1963-09-24	1966-08-16	Warner Lambert Pharmaceutical	Derivatives of quinazoline
JPS5538325A (en) *	1978-09-11	1980-03-17	Sankyo Co Ltd	4-anilinoquinazoline derivative and its preparation
US4343940A (en) *	1979-02-13	1982-08-10	Mead Johnson & Company	Anti-tumor quinazoline compounds
GB2160201B (en) *	1984-06-14	1988-05-11	Wyeth John & Brother Ltd	Quinazoline and cinnoline derivatives
EP0326307B1 (en) *	1988-01-23	1994-08-17	Kyowa Hakko Kogyo Co., Ltd.	Novel pyridazinone derivatives and pharmaceutical preparations containing them
IL89029A (en) *	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
JPH06500117A (ja) *	1991-02-20	1994-01-06	フアイザー・インコーポレイテツド	抗腫瘍活性を増強させる２，４−ジアミノキナゾリン誘導体
DE69222637T2 (de) *	1991-05-10	1998-02-26	Rhone Poulenc Rorer Int	Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5710158A (en) *	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) *	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
NZ243082A (en) *	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
US6177401B1 (en) *	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) *	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
GB9314884D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Tricyclic derivatives
GB9314893D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
WO1995006648A1 (fr) *	1993-09-03	1995-03-09	Kyowa Hakko Kogyo Co., Ltd.	Derive d'imidazoquinazoline
US5409000A (en) *	1993-09-14	1995-04-25	Cardiac Pathways Corporation	Endocardial mapping and ablation system utilizing separately controlled steerable ablation catheter with ultrasonic imaging capabilities and method
GB9325217D0 (en) *	1993-12-09	1994-02-09	Zeneca Ltd	Pyrimidine derivatives
US5700823A (en) *	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
IL112249A (en) *	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) *	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU686843B2 (en) *	1994-02-23	1998-02-12	Pfizer Inc.	4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
WO1995024190A2 (en) *	1994-03-07	1995-09-14	Sugen, Inc.	Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
EP0682027B1 (de) *	1994-05-03	1997-10-15	Novartis AG	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
GB9510757D0 (en) *	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (es)	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
DE19510019A1 (de) *	1995-03-20	1996-09-26	Thomae Gmbh Dr K	Imidazo[4,5-g]chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU5108196A (en) *	1995-03-20	1996-10-08	Dr. Karl Thomae Gmbh	Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
ES2332984T3 (es) *	1995-03-30	2010-02-16	Pfizer Products Inc.	Derivados de quinazolinas.
ATE195123T1 (de) *	1995-04-03	2000-08-15	Novartis Erfind Verwalt Gmbh	Pyrazolderivate und verfahren zu deren herstellung
GB9508535D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
GB9508537D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508565D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
WO1996033977A1 (en) *	1995-04-27	1996-10-31	Zeneca Limited	Quinazoline derivatives
IL117923A (en) *	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6020492A (en) *	1995-05-12	2000-02-01	Neurogen Corporation	Deazapurine derivatives; a new class of CRF1 specific ligands
MX9709867A (es) *	1995-06-07	1998-03-31	Pfizer	Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos.
EP0832073B1 (en) *	1995-06-07	2002-01-16	Sugen, Inc.	Quinazolines and pharmaceutical compositions
ES2172670T3 (es) *	1995-07-06	2002-10-01	Novartis Ag	Pirrolpirimidinas y procedimientos para su preparacion.
GB9514265D0 (en) *	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
AR004010A1 (es) *	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
GB9520822D0 (en) *	1995-10-11	1995-12-13	Wellcome Found	Therapeutically active compounds

1995
- 1995-04-27 GB GBGB9508538.7A patent/GB9508538D0/en active Pending
1996
- 1996-04-08 TW TW085104049A patent/TW436486B/zh not_active IP Right Cessation
- 1996-04-23 NZ NZ305444A patent/NZ305444A/xx not_active IP Right Cessation
- 1996-04-23 AT AT96910134T patent/ATE198329T1/de active
- 1996-04-23 AU AU53433/96A patent/AU699163B2/en not_active Expired
- 1996-04-23 PT PT96910134T patent/PT823900E/pt unknown
- 1996-04-23 CA CA002215732A patent/CA2215732C/en not_active Expired - Lifetime
- 1996-04-23 HU HU9802839A patent/HU223313B1/hu active Protection Beyond IP Right Term
- 1996-04-23 EG EG35896A patent/EG24134A/xx active
- 1996-04-23 UA UA97115677A patent/UA52602C2/uk unknown
- 1996-04-23 BR BRPI9608082A patent/BRPI9608082B8/pt not_active IP Right Cessation
- 1996-04-23 SI SI9630183T patent/SI0823900T1/xx unknown
- 1996-04-23 DE DE122009000076C patent/DE122009000076I1/de active Pending
- 1996-04-23 PL PL96323066A patent/PL189182B1/pl unknown
- 1996-04-23 JP JP8532252A patent/JP3040486B2/ja not_active Expired - Lifetime
- 1996-04-23 CN CN96193526A patent/CN1100046C/zh not_active Expired - Lifetime
- 1996-04-23 EE EE9700252A patent/EE03482B1/xx active Protection Beyond IP Right Term
- 1996-04-23 SK SK1454-97A patent/SK282236B6/sk not_active IP Right Cessation
- 1996-04-23 WO PCT/GB1996/000961 patent/WO1996033980A1/en not_active Ceased
- 1996-04-23 RU RU97119521/04A patent/RU2153495C2/ru active Protection Beyond IP Right Term
- 1996-04-23 KR KR1019970707511A patent/KR100296656B1/ko not_active Expired - Lifetime
- 1996-04-23 DK DK96910134T patent/DK0823900T3/da active
- 1996-04-23 EP EP96910134A patent/EP0823900B1/en not_active Expired - Lifetime
- 1996-04-23 ES ES96910134T patent/ES2153098T3/es not_active Expired - Lifetime
- 1996-04-23 RO RO97-01978A patent/RO117849B1/ro unknown
- 1996-04-23 DE DE69611361T patent/DE69611361T2/de not_active Expired - Lifetime
- 1996-04-23 CZ CZ19973396A patent/CZ288489B6/cs not_active IP Right Cessation
- 1996-04-24 AR ARP960102305A patent/AR003944A1/es unknown
- 1996-04-25 MY MYPI96001577A patent/MY114425A/en unknown
- 1996-04-25 HR HR960204A patent/HRP960204B1/xx not_active IP Right Cessation
- 1996-04-26 IL IL11804596A patent/IL118045A/en active Protection Beyond IP Right Term
- 1996-04-26 US US08/638,331 patent/US5770599A/en not_active Expired - Lifetime
- 1996-04-26 ZA ZA963358A patent/ZA963358B/xx unknown
1997
- 1997-10-24 NO NO974940A patent/NO309472B1/no not_active IP Right Cessation
- 1997-11-18 BG BG102052A patent/BG62730B1/bg unknown
2001
- 2001-01-11 GR GR20010400025T patent/GR3035211T3/el unknown
2009
- 2009-12-15 FR FR09C0065C patent/FR09C0065I2/fr active Active
- 2009-12-16 NO NO2009028C patent/NO2009028I1/no unknown
- 2009-12-17 NL NL300429C patent/NL300429I1/nl unknown
- 2009-12-17 LU LU91631C patent/LU91631I2/fr unknown

Also Published As

Publication number	Publication date
GB9508538D0 (en)	1995-06-14
HUP9802839A2 (hu)	1999-03-29
HUP9802839A3 (en)	2001-02-28
LU91631I2 (fr)	2010-02-17
CN1182421A (zh)	1998-05-20
BRPI9608082B8 (pt)	2021-07-06
HU223313B1 (hu)	2004-05-28
KR100296656B1 (ko)	2001-08-07
SK282236B6 (sk)	2001-12-03
DK0823900T3 (da)	2001-04-02
SK145497A3 (en)	1998-02-04
JP3040486B2 (ja)	2000-05-15
IL118045A (en)	2001-10-31
EP0823900B1 (en)	2000-12-27
IL118045A0 (en)	1996-08-04
GR3035211T3 (en)	2001-04-30
ATE198329T1 (de)	2001-01-15
AU5343396A (en)	1996-11-18
DE122009000076I1 (de)	2010-05-06
CA2215732A1 (en)	1996-10-31
NO309472B1 (no)	2001-02-05
KR19990007987A (ko)	1999-01-25
NL300429I1 (nl)	2010-03-01
NO2009028I2 (no)	2011-10-17
BRPI9608082A (pt)	1999-01-26
AU699163B2 (en)	1998-11-26
BG62730B1 (bg)	2000-06-30
PL189182B1 (pl)	2005-07-29
AR003944A1 (es)	1998-09-30
HRP960204A2 (en)	1997-08-31
WO1996033980A1 (en)	1996-10-31
UA52602C2 (uk)	2003-01-15
ZA963358B (en)	1996-10-28
DE69611361D1 (de)	2001-02-01
CZ339697A3 (cs)	1998-02-18
ES2153098T3 (es)	2001-02-16
FR09C0065I1 (es)	2010-01-22
EE03482B1 (et)	2001-08-15
CN1100046C (zh)	2003-01-29
NO2009028I1 (no)	2014-05-19
RU2153495C2 (ru)	2000-07-27
NO974940D0 (no)	1997-10-24
HK1005371A1 (en)	1999-01-08
PL323066A1 (en)	1998-03-02
SI0823900T1 (es)	2001-06-30
PT823900E (pt)	2001-04-30
CA2215732C (en)	2002-04-09
NO974940L (no)	1997-10-24
HRP960204B1 (en)	2001-10-31
EE9700252A (et)	1998-04-15
NZ305444A (en)	1999-03-29
EG24134A (en)	2008-08-06
CZ288489B6 (en)	2001-06-13
EP0823900A1 (en)	1998-02-18
RO117849B1 (ro)	2002-08-30
JPH11504033A (ja)	1999-04-06
TW436486B (en)	2001-05-28
US5770599A (en)	1998-06-23
MY114425A (en)	2002-10-31
BG102052A (en)	1998-08-31
BRPI9608082B1 (pt)	2019-04-30
DE69611361T2 (de)	2001-04-26

Publication	Publication Date	Title
FR09C0065I2 (fr)	2014-03-28	Derives de quinazoline
ATE205483T1 (de)	2001-09-15	Chinazolinderivate
BR9700850A (pt)	1998-09-01	Derivados de quinazolina substituídos
PT833828E (pt)	2003-02-28	Derivados de rapamicina
NO974103D0 (no)	1997-09-05	Arylsulfonylaminohydroksamsyre-derivater
DE69610698D1 (de)	2000-11-23	Chinazolin-derivate
BR9611834A (pt)	1999-03-09	Derivados de oximetóxi-3-aril-pirona
BR9605434A (pt)	1998-08-04	Derivados de purin-6-ona
ATE199150T1 (de)	2001-02-15	Diphenylmethylenpiperidin-derivate
DE69601527D1 (de)	1999-03-25	Pyrrolylbenzimidazol-Derivate
ATA100695A (de)	1998-03-15	Prothrombin-derivate
PT856007E (pt)	2004-09-30	Derivados de ciclopeptidos
BR9610597A (pt)	1999-07-06	Derivados de diarilalcenilamina
DE69627830D1 (de)	2003-06-05	Pyrazol-derivate
MA26440A1 (fr)	2004-12-20	Derives de n-benzylazolium
MA26480A1 (fr)	2004-12-20	Derives de phenoxymethylpiperidine
ATE202093T1 (de)	2001-06-15	4-amino-benzoylguanidin-derivate
DE59610106D1 (de)	2003-03-13	Fluorbenzylether-Derivate
ATE177102T1 (de)	1999-03-15	Chromanderivate
PT843675E (pt)	2002-12-31	Derivados de aza-antraciclinona
BR9603508A (pt)	1998-05-12	Derivados de alquenil-benzoilguanidina
ATE202088T1 (de)	2001-06-15	4-mercapto-benzoylguanidin-derivate
DE69620514D1 (de)	2002-05-16	5-aminoflavon-derivate
ATA45796A (de)	1999-09-15	Lysin-prolin-derivate
BR9603733A (pt)	1998-05-26	Derivados de cloropiridilcarbonila